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Introduction
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INTRODUCTION
The golden standard for diagnosing deep venous thrombosis (DVT) has
been venography for many years. Venography is an invasive, expensive and
time-consuming procedure which is not available in every hospital and not
suitable for emergency practice. Compression ultrasonography (CUS) has
mainly replaced the venography in many hospitals. The sensitivity and neg-
ative predictive value of CUS are respectively 95% and 98% for proximal
DVT (1), but are considerably lower (36-93%) for distal DVT (2-4). The
incidence of pulmonary embolism (PE) in distal DVT is 20-30%, but almost
all emboli are asymptomatic and clinically unimportant (5). A distal DVT,
however, can expand to the proximal system which has a PE incidence of
50% (5). This has resulted in the general recommendation to perform a
second CUS within one week after the initial CUS to detect a possible pro-
gression from a distal DVT to the proximal system. Only about 25% of all
patients suspected for DVT actually has thrombosis (6;7), which makes the
diagnostic procedure of repeated CUS inefficient and expensive. Newer
non-invasive strategies to reduce the need for CUS in the diagnostic man-
agement of venous thromboembolism are warranted. Major developments
in the management of screening for DVT are the renewed interest for the
clinical score and the introduction of measurement of the D-dimer concen-
tration.
The pre-test clinical probability score
The clinical appearance of DVT is heterogeneous and for a long time, the
clinical parameters have been considered to be useless. The introduction of
a new clinical assessment score (Table) has made it possible to classify
patients with a low, moderate or high pre-test clinical probability (PCP)
score, with respectively a 3%, 17% and 75% chance of having DVT (8).
The PCP score alone however, is not sensitive enough for replacing CUS. It
is also subjected to the investigators’ clinical view and thus inter-observer
variances. The PCP score may, however, have an important role in a diag-
nostic strategy where other non-invasive tools are combined.
3
Introduction
1
ch
ap
te
r
D-dimers
Plasma D-dimers are degradation products of cross-linked fibrin and thus
markers of fibrinolysis (Figure). As thrombus formation simultaneously acti-
vates fibrinolysis, the D-dimer concentration can be used as an indirect
measurement of thrombus formation. The D-dimer has a high sensitivity in
the exclusion of thrombosis (95-100%), according to the type of D-dimer
assay used (9-13). It has been suggested that a normal D-dimer concentra-
tion can be used to exclude thromboembolic processes (14), where abnor-
mal D-dimer concentrations necessitate further investigations such as
ultrasonography or venography.
The major disadvantage of the test is the frequent finding of a positive test:
increased concentrations of D-dimer levels are observed in many condi-
tions, such as infection and malignancy. This implicates that the specificity
of the test is low. 
So far, no consensus exists about the exact place of the PCP score and the
D-dimer in reducing the need for CUS in the management of patients sus-
pected for having DVT.
A score ≤ 0 is considered to be a low, 1-2 a moderate and ≥ 3 a high probability for
having deep venous thrombosis of the leg.
4
Features  Score  
Active cancer  1  
Paralysis, paresis or recent plaster immobilisation  1  
Bedridden >3 days or major surgery within 4 weeks  1 
Localised tenderness along distribution of the deep venous system  1  
Entire leg swollen  1  
Calf swelling >3cm compared with asymptomatic leg  1  
Pitting oedema (greater in symptomatic leg)  1  
Non-varicose collateral superficial veins  1 
Alternative diagnosis  -2  
Table. Pre-test clinical probability score for deep vein thrombosis (8)
Figure 
When tissue damage occurs, Tissue Factor (TF) is released, that will directly
bind with activated factor VII (VIIa) to form the TF-VIIa complex. This com-
plex activates factor X, that will transform prothrombin into thrombin (IIa).
The activation of factor X by the TF-VIIa complex not only takes place by
direct activation, but also by activation of factor IX. Thrombin stimulates its
own production by activation of factor XI and IX. The subsequent generat-
ed thrombin will split fibrinogen into fibrin monomers. Under the influence
of activated factor XIII, stable cross-linked fibrin will be formed. Fibrinolysis
of this cross-linked fibrin is induced by plasmin, and results in the formation
of fibrin degradation products. One of these products is the D-dimer. (This
model is strongly simplified)
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OUTLINE OF THE THESIS
The subject of this thesis is to refine the role of the D-dimer assay in the
diagnostic management of DVT.
CHAPTER 2 discusses laboratory aspects of the D-dimer test. Can the D-
dimer concentration be measured using heparin plasma on routine chemical
analyzers and do variances in the (pre)analytic process influence the D-
dimer determination?
The question about the time of increase and decrease of D-dimer concen-
tration after formation of a clot is addressed in CHAPTER 3. The early course
of D-dimer concentration is described after initiation of an artificial clot in
patients with hereditary hemorrhagic teleangiectasia who underwent
embolisation of pulmonary arteriovenous malformations. 
In CHAPTER 4, the clinical performance of a latex D-dimer assay in the diag-
nosis of DVT is studied. It discusses whether certain clinical or laboratory
conditions result in a lower sensitivity or specificity of the test with the pos-
sibility to restrict the use of the D-dimer test in selected patients.
The key-question is whether the D-dimer test can replace or reduce the
need for CUS in outpatients suspected for having DVT. CHAPTER 5 describes
a multicenter management study on diagnosing DVT using the combina-
tion of the PCP score, the D-dimer test and CUS. Results of the safety of
exclusion of DVT by a non-high PCP score and a normal D-dimer concen-
tration are given.
As several D-dimer assay are available, it is of interest to be informed about
the performances of different tests in the same study population. In
CHAPTER 6, five different D-dimer assays are compared using primary clinical
outcomes as sensitivity, negative predictive value and specificity for DVT.
For the early treatment of VTE, low molecular weight heparin (LMWH) has
proven to be equally effective as unfractionated heparin (UFH) from a clini-
cal point of view (15-30). CHAPTER 7 describes whether this is also true for
changes in coagulation markers during the first days of treatment of PE.
The effects of LMWH versus UFH on different coagulation and fibrinolytic
6
markers as fragment 1+2, thrombin-antithrombin complexes, fibrin mono-
mers, D-dimers and clot lysis times are described, as well as early changes in
perfusion abnormalities.
In 60-80% of all DVT, there is an identifiable underlying cause that is
responsible for the thrombophilic state. The association of thrombosis with
cancer is well known. Screening for malignancy in every patient with DVT is
laborious and expensive. In CHAPTER 8, the question is addressed whether
the height of the initial D-dimer concentration or the early course of the D-
dimer concentration during treatment for DVT can be used as a predictor
for underlying malignancy in patients with DVT.
An overview of recent published articles on the diagnostic management of
deep venous thrombosis is given in CHAPTER 9.
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No influence of heparin plasma 
and other (pre)analytic variables on 
D-dimer determination
R.E.G. Schutgens1, F.J.L.M. Haas2, H.J.T. Ruven2, 
M. Spannagl3, K. Horn3, D.H. Biesma1
Departments of 1Internal Medicine and 2Clinical Chemistry, St. Antonius
Hospital Nieuwegein, The Netherlands, and 3Central Laboratory Clinical
Chemistry, Klinikum Innenstadt, Munich University Hospital, Munich, Germany
SUMMARY
BACKGROUND Sample material for D-dimer, as for most other coagulation
tests, is citrate plasma, which is inconvenient when the test is performed on
a clinical chemistry analyzer. Other (pre)analytic variables might influence
the D-dimer determination, but are not studied extensively. We investigat-
ed the effect of heparin plasma and different (pre)analytic variables on the
D-dimer concentration. 
METHODS Heparin plasma for D-dimer concentration, using the Tina-quant®
latex assay, was compared with citrate plasma in 190 patients. The possible
influence of pneumatic mail was investigated in heparin plasma from 25
patients: one tube was transported by pneumatic mail and the other was
carried by hand. For sample stability analysis, D-dimer concentration in ran-
dom citrate plasma samples was measured immediately, after 16 and 24
hours and after having been frozen once or stored for two years at –70ºC.
For analyzer analysis, we compared D-dimer results from a Hitachi 917 and
an Integra 700 analyzer in citrate and heparin samples from 190 patients; in
145 other heparin samples, we compared the data obtained from a Hitachi
717 and an Integra 400 analyzer.
RESULTS D-dimer concentration in citrate and heparin plasma showed a per-
fect correlation (r=1.00). The D-dimer concentrations in heparin were 19%
higher than in citrate plasma, which can be attributed to the dilution by the
citrate solution. No influences of pneumatic dispatch, time of measurement,
freezing or type of analyzer on D-dimer concentrations were found.
CONCLUSIONS Our data show the validity of the determination of D-dimer
concentrations using heparin plasma. The D-dimer assay remains valid
under different (pre)analytic conditions.
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INTRODUCTION
D-dimer, a classical coagulation parameter, is increasingly used in the exclu-
sion of venous thromboembolism and the evaluation of coagulopathies. As
with all other coagulation tests, the sample material is citrate plasma. In
particular when the D-dimer test is performed on a clinical chemistry ana-
lyzer, the use of citrate plasma is a burden. Depending on whether other
coagulation tests are requested, either an extra tube for the D-dimer deter-
mination or sample splitting is needed. Furthermore, as citrate plasma used
for coagulation tests is centrifuged differently from heparin plasma and
serum, it disturbs the clinical chemistry workflow. Because D-dimer will be
used in an emergence setting, where a short turn-around time (TAT) is
mandatory, it would be advantageous if D-dimers could also be determined
in heparin plasma. 
Although many investigators have studied different D-dimer assays mainly
in search of clinical outcomes as sensitivity and negative predictive value (1-
3), it is possible that differences in the (pre)analytic processes can lead to
different results of the D-dimer assay. The influence of (pre)analytic vari-
ables on the D-dimer concentration has not been studied extensively. There
are reports on the effect of freezing on D-dimer concentration (4-7), but
the effects of transport and type of analyzer have been less studied (8;9). 
The first objective of this study is the validation of D-dimer determinations
using heparin plasma. The second objective of this study is to investigate
whether the results of a D-dimer assay are influenced by different (pre)ana-
lytic processes, such as transportation, time of measurement, freezing and
the type of analyzer used.
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METHODS
D-dimer measurement
We used the Tina-quant® (Roche, Germany) quantitative latex assay for
determination of D-dimer concentrations. Samples were collected into S-
Monovette® 9NC tubes (0.106 mol/L sodium citrate; Sarstedt, Rommels-
dorf, Germany) and S-Monovette® lithium heparin tubes (15 IU/mL
lithium-heparin). Citrate samples were centrifuged according to the 
standard protocol for coagulation samples (3000g for 15 minutes without
brake) and lithium-heparin samples were centrifuged according to the 
protocol for clinical chemistry samples (2200g for 10 minutes with brake). 
Measurements were performed on a Roche Hitachi 917 analyzer (Roche
Diagnostics GmbH, Mannheim, Germany) and a Cobas Integra 700 analy-
zer (Roche Diagnostics GmbH, Mannheim, Germany).
Pre-analytic conditions
Comparison of citrate versus heparin plasma:
Citrate and heparin plasma samples were randomly obtained from 190
patients (139 in Munich and 51 in Nieuwegein). The samples in Munich
were analyzed on a Hitachi 917 and the samples in Nieuwegein were 
analyzed on an Integra 700 analyzer.
Method for transport conditions:
From 25 patients, 2 tubes of heparin plasma were collected. One of the
heparin-plasma samples was sent to the laboratory by pneumatic mail (a
distance of approximately 100m); the other sample was carried by hand.
The samples were centrifuged as clinical chemistry samples. D-dimer con-
centration was measured on an Integra 700 analyzer. In another experi-
ment, transport was simulated by placing sample tubes on an oscillating
roller. One tube citrate plasma and two tubes of lithium-heparin plasma
from three healthy donors were obtained. The citrate sample and one of
the lithium-heparin samples were centrifuged immediately. The citrate sam-
ple was left standing at room temperature. The centrifuged lithium-heparin
plasma was split into two tubes; one was left standing at room tempera-
ture, the other tube was placed on a roller. The second lithium-heparin tube
was not centrifuged but placed directly on the roller (anticoagulated whole
14
2ch
ap
te
r
blood) and centrifuged afterwards. D-dimer concentration in all samples
was determined using a Hitachi 917 analyzer. 
Method for sample stability:
Random clinical citrate (n=15) and heparin (n=17) plasma samples were
collected from patients. The D-dimer concentration was measured directly
and measured again after the samples had stood at room temperature for
16 and 24 hours and after having been frozen once (snap-frozen in liquid
nitrogen). In addition, five citrate plasma samples from a two year old clini-
cal study, which had been stored at –70ºC, were measured. All measure-
ments except for the long term stability study were performed on a Hitachi
917. For the 2 year stability study, the D-dimer measurement was done on
an Integra 700.
Analytic conditions
Comparison of analyzers:
The first experiment was to compare a Hitachi 917 and an Integra 700 ana-
lyzer by which D-dimer concentration was measured using citrate and
heparin plasma of 190 patients.
In a second experiment, from 145 patients fresh heparin samples were
taken. D-dimer concentrations were measured on an Integra 400 and a
Hitachi 717 analyzer. The standard centrifugation protocol for clinical
chemistry samples was used, as described previously.
Statistics
For comparison of D-dimer results, the Pearson and Kendall correlation
coefficient and the Passing-Bablok regression were used. The Student t-test
was used to determine the influence of simulated transport on the D-dimer
concentration and to determine the sample stability of D-dimer concentra-
tion.
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RESULTS
Pre-analytic conditions
Comparison of citrate versus heparin plasma:
In Fig. 1, D-dimer concentrations in citrate plasma are compared with
heparin plasma. We found that the results in heparin were higher than in
citrate plasma: mean 2.51 vs 2.06 mg/L. There was a high correlation
between the citrate- and heparin plasma samples and between the two
analyzers (r=1.0, slope=1.196, Kendall tau=0.959, md(95)=0.18).
Influence of transport:
The effect of transporting heparin samples by pneumatic mail is shown in
Fig. 2. We found no difference between the two sample groups (mean 1.57
vs 1.59 mg/L; r=0.999, slope=0.993, Kendall tau=0.967, md(95)=0.09,
p=0.4). The results of simulated transport by placing sample tubes on an
oscillating roller are given in Table 1; there was no difference in D-dimer
concentrations among the samples.
Sample stability:
Results of sample stability are given in Fig. 3 for citrate plasma and Fig. 4
for heparin plasma. No differences were found between the different times
of measurement (p=0.4 for 16 h and 0.557 for 24 h in citrate plasma;
p=0.3 for 16 h and 0.3 for 24 h in heparin plasma). There was no effect of
freezing (p=0.3 for citrate-plasma samples frozen once; p=0.1 for citrate-
plasma samples stored frozen for 2 years; p=0.3 for heparin-plasma sam-
ples frozen once).
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Figure 1. D-dimer concentration in citrate versus heparin plasma on Integra 700
() and Hitachi 917() analyzers (n=190)
Figure 2. D-dimer concentration in lithium-heparin plasma with and without 
transport by pneumatic mail (n=25)
17
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Figure 3. Sample stability in citrate plasma ( after 16 hours (n=11),  after 24 
hours (n=13),  frozen 1 time (n=9), ✴ frozen 2 years (n=5))
Figure 4. Sample stability in heparin plasma ( after 16 hours (n=13),  after 24 
hours (n=16),  frozen 1 time (n=10))
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Table 1. Sample stability in simulated transport by an oscillating roller (average of
3 donors). Values in lithium-heparin plasma have been corrected for 
citrate references. Values are reported as mean ± SD. P-values indicate
differences compared to citrate plasma. 
Material and condition D-dimer (µg FEU/mL) P-value  
Citrate plasmaa 0.207 ± 0.081   
Lithium-heparin plasmab 0.253 ± 0.045 0.5
Lithium-heparin plasma rollerc 0.217 ± 0.081 0.2  
Lithium-heparin plasma whole blood rollerd 0.223 ± 0.076 0.1  
a centrifuged immediately and left standing at room temperature
b centrifuged immediately and left standing at room temperature
c centrifuged immediately and placed on an oscillating roller
d immediately placed on a roller (anti-coagulated whole blood) and centrifuged
afterwards.
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Analytic conditions
Comparison of analyzers:
Fig. 1 shows the comparison of D-dimer measurements on a Hitachi 917
and an Integra 700 analyzer. A good correlation was found (r=1.000,
slope=1.196, Kendall tau=0.959). Fig. 5 shows the comparison of D-dimer
measurements in heparin plasma on a Hitachi 717 and Integra 400 analyz-
er. No differences were found (r=0.999, slope=1.0165, Kendall tau=0.950).
Figure 5. D-dimer determination in lithium-heparin plasma on Integra 400 and 
Hitachi 717 analyzers (n=145)
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DISCUSSION
Our data confirm and extend the previous report of Vukovich et al (10) on
the validity of performing the Tina-quant D-dimer test using heparin plas-
ma rather than the standard measurements in citrate plasma. This finding
substantially decreases the TAT of the D-dimer test by reducing pre-analytic
processing. We estimate that, in our hospital, this TAT has been reduced
from 60 to 30 minutes. Our observation has an important consequence for
the use of D-dimer measurements in emergency settings, where it is a pre-
requisite to perform a reliable test with a short TAT. It also implicates that a
D-dimer test performed on a chemical analyzer can compete with the
newer point-of-care D-dimer tests: the latter D-dimer tests have less exten-
sively been validated and their advantage from a time-consuming point of
view is now being diminished. 
We found the D-dimer concentration in heparin plasma to be higher than
in citrate plasma, with an average of 19%. This can be explained by the
fact that there is no dilution in the heparin plasma, whereas this is the case
in the citrate solution. This percentage was identical in both centers that
participated in this study. As all reports in literature are based on the stan-
dard citrate solution, we therefore multiply the results in the heparin sam-
ples by a factor of 0.84 (=1/1.19) to avoid the need for a change in
reference and cut-off values. This correction factor is in accordance with the
correction factor that has been found by Vukovich et al (10) and corre-
sponds with what one would theoretically expect when 1 part citrate solu-
tion and 9 parts blood with a hematocrit of 42% are taken together (11).
The D-dimer concentration in lithium-heparin plasma in our study is unaf-
fected by transport by pneumatic mail or by rough handling, simulated by
placing the sample on an oscillating roller. This opens the possibility of
pneumatic dispatch of the sample tubes and thus a gain in time at the
emergency department. It also indicates that samples obtained by general
practitioners or local hospitals with limited capacity can be transported to a
central laboratory for D-dimer measurements without decreasing their
quality. That means that patients do not necessarily have to go to the emer-
gency room for D-dimer determinations. 
We found that the D-dimer concentrations in citrate and heparin plasma
were stable regardless of the time of measurement, freezing or the type of
analyzer used. This indicates that it is valid to perform studies on frozen
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material and that test results of the Tina-quant® assay, obtained under dif-
ferent (pre)analytic conditions, can be compared without loss of reliability.
In conclusion, measurement of D-dimer concentrations with the Tina-
quant® D-dimer test using heparin plasma is valid and provides a reduction
in TAT. The D-dimer assay remains valid under different (pre)analytic condi-
tions.
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The early course of D-dimer 
concentration following 
pulmonary artery embolisation
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SUMMARY
BACKGROUND There is little information about the course of D-dimer concen-
tration in patients during the first hours of a thrombotic event. We meas-
ured D-dimer concentrations following pulmonary artery embolisation in
patients with pulmonary arteriovenous malformations.
METHODS We studied D-dimer concentration before and during an 8-hour
time period after embolisation in 13 patients; the control group were 14
patients with a diagnostic heart catheterisation without embolisation. 
We investigated the extent of D-dimer concentration in relation to the total
volume of the parts of the embolised arteries, the improvement in pO2 and
the reduction in shunt fraction.
RESULTS The patients had significantly increased D-dimer levels at t=2, 4 and
8 hours after the procedure as compared to baseline (p=0.001) and to the
controls (p=0.047). We found a correlation between D-dimer concentration
and the calculated volume of the embolised arteries (R2=0.74).
CONCLUSIONS There is no relevant lag time between the increase in D-dimer
concentration and pulmonary embolisation. The relation between D-dimer
concentration and thrombus size deserves confirmational studies.
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INTRODUCTION
The onset of venous thromboembolic processes is accompanied by an
increase in the concentration of D-dimers, which are products of the plas-
min-mediated proteolysis of cross-linked fibrin. Measurement of D-dimer
concentration is considered to be a promising tool in the reduction of addi-
tional tests to rule out venous thromboembolism (VTE). Sensitivity and neg-
ative predictive value of D-dimer tests have been investigated in several
management studies (1-4). Although some authors suggest that anticoagu-
lant therapy can be withheld in patients with normal D-dimer levels (5;6),
studies about the accuracy of different D-dimer tests show large variations
in sensitivity and negative predictive value (7-9). A source of variation in D-
dimer concentration may be the time of D-dimer determination in relation
with the duration of symptoms or the onset of the thromboembolic process
(10;11). Data about the course of D-dimer concentration in patients with
VTE are limited to a study during the first days of heparin treatment in
patients with deep venous thrombosis (12). It is of clinical importance to be
informed about the time of increase and decrease in D-dimer concentration
to establish the optimal time of D-dimer testing and to define the time-
period before and after which a D-dimer test may have reduced accuracy.
In addition, it is of interest to be informed about the correlation between
the size of the thrombus and the extent of D-dimer concentration, as large
thrombi may lead to a more aggressive therapeutic approach and to a more
careful monitoring.
We studied the course of D-dimer concentrations in patients undergoing
embolisation of pulmonary arteries because of pulmonary arteriovenous
malformations (PAVM) that caused hypoxemia and right-to-left shunts. We
also calculated the correlation between D-dimer concentrations and the
estimated size of the thrombus.
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PATIENTS AND METHODS
Patients
We studied 13 patients with hereditary hemorrhagic teleangiectasia (HHT)
or Rendu-Osler-Weber disease who underwent embolisation because of
PAVM causing hypoxemia and increased right-to-left shunts. Embolisation
in patients with PAVM induces thrombus formation due to local haemosta-
sis in the presence of thrombogenic fibres attached to coils. The patient
group consisted of 13 individuals (3 men and 10 women) with a mean age
of 39.9 ± 12.2 years (range: 23-66 years). The control group consisted of
14 patients (8 men and 6 women) with a mean age of 56.3 ± 17.5 years
(range: 23-82 years) who underwent a diagnostic right and/or left heart
catheterisation procedure with pulmonary or coronary angiography without
any intervention. The individuals in the control group were suspected of
aortic or mitral insufficiency (n=4), aortic stenosis (n=1), coronary insuffi-
ciency (n=2), HHT (n=3), pulmonary hypertension (n=2), Scimitar syn-
drome (n=1) or screened for lung transplantation (n=1). Patients and
controls did not use oral anticoagulants. 
Methods
The catheterisation in both groups was carried out by right heart catheteri-
sation through a femoral approach. The quantity of heparin to flush the
catheter in the embolised group was at least 3000 IU with a maximum of
5000 IU depending on the length of the procedure. The control group
received a standard dose of 5000 IU heparin. There was no significant dif-
ference in the median dose of heparin used in patients and controls. The
duration of the procedure was 1-3 hours in both groups. For the embolisa-
tion, we used coils made of platinum with and without synthetic fibres
(Cook, Denmark and Target Therapeutics, Ireland). Blood was collected two
hours before, at the start of and two, four and eight hours after the proce-
dure. We used the Asserachrom® ELISA (Diagnostica Stago, France) for the
determination of D-dimer concentrations. All patients gave informed con-
sent and the medical ethical committee of the St. Antonius Hospital
approved the study protocol. 
The size of the thrombus induced by the coils was estimated in three differ-
ent ways. We calculated the total volume of the parts of the pulmonary
arteries that were embolised (∑πr2x length). 
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We calculated the reduction of the right to left shunt measured with 100%
oxygen, as described previously (13-15). Finally, we measured differences
in pO2 (in kPascal) before and after the embolisation.
Statistics
Between groups repeated measurements ANOVA was used (α-levels were
0.05). Data are given as mean ± standard error of the mean. For calculation
of correlation Pearson’s correlation and p-values were used.
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RESULTS
The course of D-dimer concentration determined by the Asserachrom®
ELISA assay in the patient and control group is shown in Fig. 1. The results
at t=-2 and t=0 hours were similar and combined at t=0 hours. At the start
of the procedure, no differences in D-dimer concentration were found
between the two groups. At t=2 hours, D-dimer concentration in the
patient group was significantly higher as compared to D-dimer concentra-
tion at baseline (p=0.001). The D-dimer values obtained at t=4 hours and
t=8 hours remained significantly higher when compared to baseline
(p=0.02 and p=0.001 respectively). The control group showed no signifi-
cant increase in D-dimer concentration as compared to baseline. The
increase in D-dimer concentration in the patient group differed significantly
from the control group (p=0.047).
We found a correlation between D-dimer concentration and the calculated
volume of the parts of the pulmonary arteries that were embolised
(R2=0.74, p<0.001) (Fig. 2), but not between D-dimer concentration and
the decrease of the right to left shunt or the increase in pO2 (R2=0.26,
p=0.1 and R2= 0.06, p=0.5 respectively).
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Figure 1. Course of D-dimer concentration following pulmonary embolisation in 
patients with pulmonary arteriovenous malformations. Controls under
went diagnostic heart catheterisation without intervention. 
Figure 2. Relationship between D-dimer concentration and calculated surfaces of 
the parts of the embolised arteries following pulmonary embolisation.
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DISCUSSION
Determination of D-dimer concentration is increasingly used as diagnostic
tool for exclusion of VTE. The moment of D-dimer determination in pul-
monary embolism (PE) varies from an immediate diagnostic procedure in
patients with sudden onset of dyspnoea and chest-pain to a delayed proce-
dure in patients with unexplained thoracic complaints for a longer period.
The exact time after which D-dimer concentrations begin to rise and fall
after the formation of a clot in humans is unknown. Because PE is often
preceded by the formation of a thrombus in the legs, our model of PAVM-
embolisation may not be identical to the events in patients with PE. Our
study mimics, however, some of its aspects and provides data about the D-
dimer concentration in the first hours after a thromboembolic event.
In this study in patients with PAVM undergoing embolisation, we observed
a significant increase in D-dimer concentration at 2 hours after the start of
embolisation, which remained significantly elevated during 8 hours. This
implicates that D-dimer concentrations show an almost immediate increase
after the start of embolisation and makes the existence of a lag time unlike-
ly. A significant time by group interaction was present, which means that
the differences in D-dimer concentration between patients and controls
increased during the observation period of 8 hours and that the increase of
D-dimer was not due to the catheterisation alone. The clinical implication of
this finding is that D-dimer concentrations remain elevated for at least the
first 8 hours after the onset of thrombosis.
In a previous study, a trend but not a significant correlation was found
between D-dimer levels and the location of VTE (16). In the present study,
we found a correlation between D-dimer concentrations and the calculated
volume of the parts of the pulmonary arteries that were embolised. This
may indicate higher D-dimer levels to be present in larger thrombus forma-
tions. The fact that we did not find a correlation between D-dimer levels
and differences in shunt fraction and pO2 after embolisation may be due to
the fact that the latter two are indirect estimates of thrombus formation,
while measurement of the volume of the arteries is a more direct approach.
Furthermore, there may be inter-individual differences in fibrinolytic activity
after a thromboembolic event. However, as functional impairment is more
relevant than the size of the thrombus, it is -in our opinion- not correct to
delay further tests (such as pulmonary angiography) in patients suspected
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for having PE with only small increases in D-dimer concentration and non-
diagnostic ventilation-perfusion scans.
In conclusion, we found no relevant lag time between the increase in D-
dimer concentration and pulmonary embolisation in patients with PAVM.
D-dimer concentrations remain elevated during at least the first 8 hours of
a thrombotic event. The D-dimer concentration may be helpful to predict
the extent of thrombus formation.
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CHAPTER  4
Usefulness of a semiquantitative 
D-dimer test for the exclusion of deep
venous thrombosis in outpatients
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SUMMARY
BACKGROUND The D-dimer test is used commonly in diagnostic strategies to
reduce the need for ultrasonography in patients suspected of having deep
venous thrombosis. We studied several clinical and laboratory variables that
might limit the accuracy of a semiquantitative D-dimer test.
METHODS In this retrospective cohort study, 704 outpatients suspected of
having deep venous thrombosis underwent a semiquantitative D-dimer test
and ultrasonography. The performance of the D-dimer test was calculated
in patients using anticoagulants (n=61), patients with previous thrombosis
(n=127), and patients with malignancy (n=47), including 39 patients with
more than one of these characteristics. The 508 remaining patients were
considered to be the reference group.
RESULTS A total of 254 patients (36%) had evidence of deep venous throm-
bosis. The D-dimer test had a sensitivity of 99% (174/176; 95% confi-
dence interval [CI]: 96% to 100%) and a negative predictive value of 98%
(98/100; 95% CI: 93% to 100%) in the reference group. The sensitivity of
the D-dimer test in patients using oral anticoagulants was 75% (6/8; 95%
CI: 35% to 97%; p=0.01 compared with the reference group). Test sensi-
tivity was 96% (51/53; 95% CI: 87% to 100%) in patients with previous
thrombosis, and 100% (29/29; 95% CI: 88% to 100%) in patients with
cancer. However, 553 (79%) of all patients, including 43 of the cancer
patients (91%), had an abnormal D-dimer test.
CONCLUSIONS The semiquantitative D-dimer test in this study has a high sen-
sitivity and negative predictive value in the exclusion of deep venous
thrombosis, except perhaps among patients using oral anticoagulants. D-
dimer tests in patients with cancer and in patients over 70 years old may
not be worthwhile, as the tests are usually positive. 
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INTRODUCTION
Diagnosing deep venous thrombosis remains a challenge. The current diag-
nostic strategy usually consists of performing an ultrasonography of the
femoral and popliteal veins; this test is repeated within 1 week if the initial
examination was negative. It is safe not to anticoagulate patients with
repeated normal ultrasonography (1;2). However, only 15% to 28% of
patients suspected of having deep venous thrombosis actually have a
thrombosis (1-4), and only 1% of patients with an initially normal ultra-
sonography develop deep venous thrombosis within 1 week (1;2). This has
led to a search for a more efficient diagnostic strategy.
Plasma D-dimer levels, which measure the degradation products of cross-
linked fibrin, are a valuable diagnostic test for the exclusion of deep venous
thrombosis, and it is safe to withhold anticoagulant treatment in patients
with a single negative ultrasonography and a negative D-dimer test (2). In
addition, the combination of clinical assessment and a normal D-dimer test
might also reduce the need for ultrasonography (5-7). There is a wide
range, however, in the diagnostic accuracy of D-dimer tests. The first gen-
eration of rapid latex agglutination assays, which can be used in an emer-
gency and bedside setting, has considerably lower sensitivity and negative
predictive values than do the classic enzyme linked immunosorbent assays
(ELISA) (8-10). Newer, fully-automatic, quantitative rapid latex and ELISA
tests may be more accurate (8-10), but are more expensive and are not
widely available. 
A major disadvantage of measuring D-dimer levels is the frequent finding
of a positive test; thus ultrasonography is still needed in the majority of
patients suspected of having deep venous thrombosis. It might save both
time and health care costs to avoid measuring D-dimer levels in patients
with a high a priori likelihood of having a positive test. Therefore, we
sought to determine the usefulness of a latex D-dimer test in excluding
deep venous thrombosis, as well as to define clinical variables (such as use
of oral anticoagulants, previous deep venous thrombosis, malignancy, age)
or laboratory variables (renal function, complete blood count) that may
affect its usefulness in a cohort of 704 outpatients suspected of having
deep venous thrombosis.
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PATIENTS AND METHODS
Patients and methods
We retrospectively identified 711 consecutive outpatients who had been
suspected of having deep venous thrombosis from November 1994 to
December 2000. We excluded 3 women who were pregnant and 4 patients
who had a history of a previous deep venous thrombosis without docu-
mented recanalization. At initial presentation, all 704 remaining patients
underwent ultrasonography of the symptomatic leg and a D-dimer test.
The ultrasonography was repeated within 1 week if the first examination
was negative for deep venous thrombosis. If the ultrasonography was posi-
tive for deep venous thrombosis, the patient was treated with anticoagu-
lants. Data from a 6-month follow-up were obtained by visit or telephone
contact with the patient or the general practitioner. We recorded patients’
sex, age, use of oral anticoagulants, previous venous thromboembolism,
and active malignancy (defined as receiving any treatment for cancer or
documented recurrent or metastatic disease). Patients without use of oral
anticoagulants, previous venous thromboembolism, or malignancy were
assigned as the reference group. We also recorded serum creatinine levels
and complete blood counts at the time of presentation. The medical ethics
committee of our hospital approved the study protocol.
Ultrasonography, using real-time B-mode with compression, was performed
with a 7.5-MHz or a 5.0-MHz transducer. Two areas of the leg were exam-
ined: the common femoral vein at the inguinal ligament and the popliteal
vein at the knee-joint line traced down to the point of the trifurcation of
the calf veins. Veins were scanned in the transverse plane only. Lack of
compressibility was the sole criterion for an abnormal result; a vein was
considered fully compressible if no residual lumen was seen.
The D-dimer test used was the Minutex® (Biopool, Umeå , Sweden), used
as a semiquantitative test by dilutions. We made a range of samples: the
undiluted sample and the sample diluted with buffer 1 + 1, 1 + 3, and 1 + 7.
The results are reported as negative, 1+, 2+, 3+, or 4+; 1+ or more was
considered to be a positive test result. The tests were performed under
standard conditions, using a magnifying glass with a lamp, a black back-
ground, and positive and negative control plasma samples.
Laboratory measurements of creatinine were performed by routine meth-
ods using an Integra 700 analyzer (Roche, Mannheim , Germany). 
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Complete blood count measurements were performed using Gen S (Beck-
man Coulter, Fullerton, California ).  
Statistics 
We calculated the sensitivity, specificity, negative predictive value, and posi-
tive predictive value, including 95% confidence intervals, for the D-dimer
test. The Fisher exact test (two-tailed) was used to compare proportions.
The Cochran-Armitage test for trend was used to compare multiple propor-
tions. For the analysis of the association between age and D-dimer levels,
only patients without proven deep venous thrombosis (n=450) were includ-
ed to eliminate bias from the higher prevalence of thrombosis in elderly
patients. General linear regression models were used to compare continu-
ous laboratory variables with categorical D-dimer results. SAS software
(Cary, North Carolina) and Confidence Interval Analysis (London, United
Kingdom) were used for all calculations. 
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RESULTS
The sample consisted of 704 patients with a mean (± SD) age of 59 ± 17
years. Of the 464 patients with an initial normal ultrasonography, 187
(40%) underwent a second ultrasonography. Deep venous thrombosis was
diagnosed in 254 patients (36%), 240 of whom were diagnosed at presen-
tation and 14 during 6-month follow-up (10 by the second ultrasonogra-
phy within 1 week, 2 at 8 weeks, 1 at 3 months, and 1 at 5 months). All 14
of these patients had a positive D-dimer test at presentation. In the 464
patients with an initial normal ultrasonography, 6-month follow-up data
were obtained by visit in 361 patients (78%) and by telephone contact in
103 patients (22%).
Performance of the D-dimer test
The sensitivity and negative predictive value of the D-dimer test were high
(≥ 97%), particularly among patients who did not use anticoagulants or
have a history of deep venous thrombosis or cancer (the reference group;
Table).  A deep venous thrombosis was detected by ultrasonography in 4
patients with a negative D-dimer test, of whom 2 used oral anticoagulants. 
Sensitivity was lower among the 61 patients using oral anticoagulants; of
the 8 patients with deep venous thrombosis in this group, 2 had a negative
D-dimer test. Anticoagulated patients were more likely to have a negative
D-dimer test than was the reference group (46% [28/61] vs. 20%
[100/508], p<0.001). Sensitivity and negative predictive value did not differ
statistically among patients with a previous deep venous thrombosis (n =
127) when compared with the reference group (Table). Both of the 53
patients with thrombosis in this group who had a negative D-dimer test
were using oral anticoagulants.
All 29 of the 47 patients with cancer who had a deep venous thrombosis
had a positive D-dimer test; however, so did all but 4 of those without
venous thrombosis, a specificity of only 22% (Table). Excluding the 7
patients with cancer who used oral anticoagulants did not significantly
improve the specificity.
The positive predictive value of the D-dimer test increased with higher D-
dimer concentrations (Figure 1). The prevalence of a positive D-dimer test
increased with age (p<0.001; Figure 2). This association remained after
adjustment for the use of oral anticoagulants, previous venous thromboem-
bolism, cancer, and sex. Of the 156 patients aged ≥70 years, 79% (n =
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123) had a positive D-dimer test, compared with 61% (180/294) of
younger patients (p=0.0001).
There was a significant inverse correlation between D-dimer level and the
hemoglobin concentration (R=-0.17, p=0.01). Of the 704 patients, data on
hemoglobin concentration were available in 513 patients. The mean hemo-
globin concentration in the 114 patients with a negative D-dimer test was
13.7 ± 1.4 g/dL, compared with 13.0 ± 1.9 g/dL in the 109 patients with a
D-dimer level of 4+ (p=0.01). No correlation was found between D-dimer
level and the leukocyte count (R=0.06, p=0.7), platelet count (R=0.05,
p=0.9), or serum creatinine concentration (R=0.14, p=0.06).
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Figure 1. The positive predictive value of the D-dimer test according to D-dimer 
concentrations among outpatients suspected of having deep venous 
thrombosis.
Figure 2. The prevalence of a positive D-dimer test according to age among 
outpatients suspected of having deep venous thrombosis, who did not 
have thrombosis after objective testing.
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DISCUSSION
To develop practical guidelines for the use of the D-dimer test in the man-
agement of patients suspected of having a deep venous thrombosis, we
studied several clinical and laboratory variables that might affect the test’s
sensitivity or specificity. The rapid latex D-dimer assay that we used had
excellent sensitivity and negative predictive value in outpatients, with the
possible exception of those who used oral anticoagulants. The previously
reported lower sensitivity and negative predictive value of this latex 
D-dimer assay may be the result of differences in the preanalytic and ana-
lytic process (8-10). For example, Janssen et al. performed this test on
frozen and stored samples (8). A more common problem with the rapid
latex D-dimer test is that its interpretation is influenced by inter- and
intraobserver variability. In our laboratory, we used standard conditions and
skilled technicians. 
Patients using oral anticoagulants had a significantly lower sensitivity when
compared with the reference group, although there were only 8 patients
with a deep venous thrombosis in this group. This finding may be explained
by a reduced capacity for thrombin generation and plasma D-dimer forma-
tion in patients taking oral anticoagulants (11;12). This is consistent with
the significant increase in D-dimer levels after cessation of anticoagulant
therapy (13) and the normalization of elevated D-dimer levels after begin-
ning their use (14). Although larger studies are warranted to confirm our
findings, we have decided not to use the D-dimer test to exclude deep
venous thrombosis in patients using oral anticoagulants.
We also found that the D-dimer test can be used to exclude renewed
thrombotic activity in patients with previous venous thrombosis, since the
sensitivity and negative predictive value of the test were not different from
the reference group. As an initial screening in patients with a history of
deep venous thrombosis, the D-dimer test is probably more reliable than an
ultrasonography when renewed thrombotic activity is suspected.
Ultrasonography is less sensitive in the case of distal thrombosis (15) and
has a high rate of false-positive results due to persisting venous abnormali-
ties (16).
Only 4 of the 47 patients with malignancy had a negative D-dimer test.
Elevated D-dimer levels in patients with malignancy might be the result of
production of procoagulant proteases by tumor cells, leading to subclinical
intravascular coagulation (17). However, local rather than systemic fibrin
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formation may be a more likely cause of elevated D-dimer levels (18). In
our opinion, the high prevalence of a positive D-dimer test result, along
with its low specificity, suggest that the assay may not be useful as a
screening test in patients with cancer. We did not, however, confirm the
results of a study that reported the low negative predictive value of a D-
dimer test in patients with cancer (19).
As has been reported (20-23), D-dimer tests were more likely to be positive
with aging, perhaps due to a greater prevalence of comorbid conditions. Of
the 156 patients older than 70 years who did not have deep venous throm-
bosis, almost 80% (n = 123) had a positive D-dimer test, compared with
61% (180/294) of patients younger than 70 years. Therefore, it is ques-
tionable whether the D-dimer test is useful in older patients. The cost-effec-
tiveness of the D-dimer test in elderly patients should be determined. In
addition, hemoglobin levels were indirectly proportional to D-dimer levels,
perhaps because anemia often occurs in chronic inflammatory disorders
that also may lead to increased D-dimer levels.  
In conclusion, the sensitivity and negative predictive value of this rapid latex
D-dimer assay for the exclusion of deep venous thrombosis are high. The
D-dimer test has a good performance in patients with previous venous
thromboembolism, but we do not recommend its use in patients using oral
anticoagulants because of the reduced sensitivity of the test. D-dimer tests
in patients with cancer and in patients over 70 years old may not be worth-
while, as the tests are usually positive. 
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CHAPTER  5
The combination of a normal D-dimer
concentration and a non-high pretest
clinical probability score is a safe 
strategy to exclude deep venous 
thrombosis
R.E.G. Schutgens1, P. Ackermark2, F.J.L.M. Haas3, 
H.K. Nieuwenhuis4, H.G. Peltenburg5, A.H. Pijlman2, 
M. Pruijm5, R. Oltmans6, J.C. Kelder7, D.H. Biesma1.
Departments of 1Internal Medicine, 3Clinical Chemistry and 7Research and
Development, St. Antonius Hospital, Nieuwegein; 2Internal Medicine,
Diakonessenhuis, Utrecht; 4Haematology, University Medical Centre, Utrecht;
5Internal Medicine, Groene Hart Hospital, Gouda; 6Internal Medicine, 
Mesos Medical Centre, Utrecht; The Netherlands
SUMMARY
BACKGROUND Serial ultrasonography is reliable for the diagnosis of deep
venous thrombosis in symptomatic patients, but the low prevalence of
thrombosis in this group renders this approach costly and inconvenient to
patients. We studied the clinical validity of the combination of a pretest
clinical probability score and a D-dimer test in the initial evaluation of
patients suspected of deep venous thrombosis.
METHODS Patients with a normal D-dimer concentration (< 500 FEU µg/L)
and a non-high probability score (< 3) had no further testing. Patients with
a normal D-dimer concentration and a high probability score (≥ 3) under-
went one ultrasonography. Serial ultrasonography was performed in
patients with an abnormal D-dimer concentration. Patients were followed
for 3 months.
RESULTS A total of 812 patients were evaluable for efficacy. Only 1 of 176
patients (0.6%; 95% CI: 0.02-3.1%) with a normal D-dimer concentration
and a non-high probability score developed thrombosis during follow-up. A
normal D-dimer concentration and a high probability score were found in
39 patients; 3 of them (7.7%; 95% CI: 1.6-20.9%) had thrombosis at pres-
entation, and one (2.8%; 95% CI: 0.07-14.5%) developed pulmonary
embolism during follow-up. In 306 of 597 patients (51.3%) with an abnor-
mal D-dimer concentration, thrombosis was detected by serial ultrasonog-
raphy. Six patients (2.1%; 95% CI: 0.8-4.4%) developed thrombosis during
follow-up. No deaths due to thromboembolism occurred during follow-up.
The total need for ultrasonography was reduced by 29%.
CONCLUSIONS The combination of a non-high pretest clinical probability
score and a normal D-dimer concentration is a safe strategy to rule out
deep venous thrombosis and to withhold anticoagulation.
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INTRODUCTION
Deep venous thrombosis can be diagnosed or rejected accurately by serial
compression ultrasonography. In two studies with a follow-up period of,
respectively, 3 and 6 months, venous thromboembolic complications were
found in only 0.6% and 0.7% of patients with suspected deep venous
thrombosis after normal serial ultrasonography (1;2). Serial ultrasonogra-
phy, however, is inefficient because only 17 to 24% of patients suspected
for deep venous thrombosis actually has it (1-6), and only 0.9% develop it
after the initial normal ultrasonogram (2). Other non-invasive diagnostic
tests, such as the pretest clinical probability score (5-7) and the D-dimer
measurement (4;7-14), are subject of studies to reduce the need for ultra-
sonography. It has been proven safe to withhold anticoagulant treatment in
patients with a low pretest clinical probability score and normal initial ultra-
sonogram (6) and in patients with a normal D-dimer and normal ultra-
sonography at first presentation (3;11;14). The next step, which is the
subject of the present study, is to investigate the safety of the combination
of a non-high pretest clinical probability score and a normal D-dimer to
replace of ultrasonography as the initial test in the diagnostic management
of patients suspected of having deep venous thrombosis.
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PATIENTS AND METHODS
Patients
This investigation was a prospective cohort study in 4 large, nonacademic,
teaching hospitals in the Netherlands. All outpatients with clinical symp-
toms of deep venous thrombosis of the leg, who were referred by their
general practitioners, were potentially eligible for the study. Exclusion crite-
ria were pregnancy, previous deep venous thrombosis in the ipsilateral leg
without documentation of recanalization, a concomitant clinical suspicion
of pulmonary embolism, the use of unfractionated heparin, low-molecular-
weight heparin or any form of oral anticoagulant in the past month, geo-
graphic impossibility for follow-up and life expectancy less than 3 months.
Patients entering the study were asked for informed consent. The medical
ethical committees of the participating centers approved the study.
Methods
Eligible patients who gave informed consent were assessed by one of the
study physicians or local residents and a single pretest clinical probability
score according to Wells et al was performed (5). Patients were considered
to have a low or moderate (“non-high”) suspicion for having deep venous
thrombosis when the score was < 3 and at high suspicion when the score
was ≥ 3. We performed the Tina-quant® quantitative latex D-dimer assay
(Roche, Germany) in all patients. Previous reports have validated this test
using venography (12;15). An abnormal test was defined as a D-dimer-
value > 499 Fibrin Equivalent Units (FEU) µg/L. The pretest clinical proba-
bility score was performed by physicians who were not previously aware of
the D-dimer concentration.
Ultrasonography, using real-time B-mode with compression, was done with
a 7.5 MHz and/or a 5.0 MHz transducer. Two areas of the leg were exam-
ined: the common femoral vein at the inguinal ligament and the popliteal
vein at the knee-joint line traced down to the point of the trifurcation of
the calf veins. Veins were scanned in the transverse plane only. Lack of
compressibility was the sole criterion for an abnormal result; a vein was
considered fully compressible if no residual lumen was seen. 
Patients with a non-high pretest clinical probability score and a normal 
D-dimer concentration had no further investigations (Figure). The patients
with a high pretest clinical probability score and a normal D-dimer concen-
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tration underwent a single ultrasonogram at presentation. Patients with an
abnormal D-dimer concentration (irrespective their pretest clinical probabili-
ty score) had repeated ultrasonography (with a second ultrasonography
after 1 week). Patients who had no further investigations and patients with
normal ultrasonography results did not receive anticoagulation. These
patients were followed for 3 months and data from this 3-month follow-up
were obtained by visit or telephone contact with the patient or the general
practitioner. Patients were instructed to contact their physician when symp-
toms of their leg worsened or when symptoms of pulmonary embolism
occurred. Worsening of complaints of the leg, new complaints of the leg or
respiratory tract, or an objective clinical change in the patient were followed
by objective testing using ultrasonography, ventilation-perfusion scintigra-
phy or pulmonary angiography. The primary outcome of this study was the
development of thromboembolic processes (deep venous thrombosis or
pulmonary embolism) during the 3-months follow-up period. 
Statistics
For calculation of 95% confidence intervals (CI), the exact binomial method
was used.
Figure. Diagnostic flowchart for patients with suspected deep venous thrombosis.
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RESULTS
During the study period, 902 consecutive outpatients with suspected deep
venous thrombosis were referred. Of these patients, 827 (92%) were eligi-
ble and gave informed consent. There were 75 ineligible patients (Table 1).
Of the 827 patients included in the study, 812 patients were fully evaluable
(mean age 59 ±17 years; 518 (64%) women). None of the patients used
tranexamic acid. The 15 patients that were not fully evaluable were exclud-
ed from the final analysis of the study (i.e. the 3-month thromboembolic
risk): one patient (with normal serial ultrasonography) was lost to follow
up, 6 patients received oral anticoagulation for reasons other than throm-
boembolism during follow up, 4 patients had protocol violation, and 4
patients died during follow-up. The 4 patients that died all had a positive
D-dimer and normal serial ultrasonography, and the cause of death was not
related to thrombosis. None of these 15 patients had venous thromboem-
bolism at time of exclusion from the study.
The main results of this study are given in Table 2. Deep venous thrombosis
or pulmonary embolism was diagnosed in 317 (39%) patients during the
entire study period. Deep venous thrombosis was diagnosed at initial
screening in 309 patients by single or serial ultrasonography; 8 patients of
the remaining 503 patients (1.6%; 95% CI: 0.7-3.1%) developed deep
venous thrombosis or pulmonary embolism during the 3-months follow-up
period. No deaths due to venous thromboembolism were observed during
the follow-up period.
In the group of patients with a non-high pretest clinical probability score
and normal D-dimer concentration, deep venous thrombosis was found
during follow-up in one patient (0.6; 95% CI: 0.02-3.1%). This patient
returned to the hospital because of worsening of complaints 2 days after
first presentation; at that time the D-dimer was abnormal and a deep calf
vein thrombosis was detected by a single ultrasonogram. This patient
seemed to be heterogeneous for the factor V Leiden mutation. The diag-
nostic strategy performed in this group had a negative predictive value of
99.4% (95% CI: 96.9-100%). There were no deaths in this group. The
prevalence of a low or moderate clinical probability score in this group was
49% (87 of 176 patients) and 51% (89 of 176 patients), respectively.
Three of the 39 patients (7.7%; 95% CI: 1.6-20.9%) with a normal D-
dimer concentration and a high pretest clinical probability score had deep
venous thrombosis on ultrasonography at presentation; one out of the
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remaining 36 patients (2.8%; 95% CI: 0.07-14.5%) developed pulmonary
embolism at 71 days after initial screening. At that time, the D-dimer con-
centration was abnormal and repeated ultrasonograms remained normal.
This patient seemed to have an abdominal localized non-Hodgkin lym-
phoma that impaired lymph drainage from the legs. The negative predictive
value of this regimen was 97.2% (95% CI: 85.5-99.9%). No deaths were
reported in this group.
In patients with an abnormal D-dimer concentration (n=597), 291 had
deep venous thrombosis detected by the first ultrasonogram, and 15
patients had it detected by the second ultrasonogram. Six of the 291
patients (2.1%; 95% CI: 0.8-4.4%) with normal serial ultrasonography
developed venous thromboembolism during the 3-month follow-up period
(3 deep venous thromboses and 3 pulmonary embolisms). Of these 6
patients, one was heterogeneous for the factor V Leiden mutation, one had
a non-Hodgkin lymphoma and one had a previous history of venous
thromboembolism and was using oral anticonceptives. The diagnostic strat-
egy in the group with serial ultrasonography had a negative predictive
value of 97.9% (95% CI: 95.6-99.2%). The prevalence of a low, moderate,
or high clinical score in the group with abnormal D-dimer concentrations
was 19% (114 of 597 patients), 41% (243 of 597 patients), and 40% (240
of 597 patients), respectively. The prevalence of DVT in these three clinical
probability groups was 22%, 51%, and 68%, respectively.
If exclusion of deep venous thrombosis would have been based on a nor-
mal D-dimer concentration alone (ie, not using the pretest clinical probabili-
ty score), we would have missed deep venous thrombosis in 5 of 215
patients (2.3%; 95% CI: 0.8-5.3%) with a normal D-dimer concentration;
this strategy would have a negative predictive value of 97.7% (95% CI:
94.7-99.2%). The sensitivity of the D-dimer was 98.4% (95% CI: 96.4-
99.5%; 312 of 317 patients), and its specificity 42.4% (95% CI: 38.1-
46.8%; 210 of 495 patients).
Analysis of the clinical probability score in the 812 patients showed that
24.8% (201 of 812 patients) had a low probability score, 40.9% (332 of
812 patients) a moderate and 34.3% (279 of 812 patients) a high probabil-
ity score. The prevalence of deep venous thrombosis in the three probability
categories was 12.9%, 37.7%, and 59.5%, respectively. The sensitivity of
the D-dimer in patients with a low probability score was 96.2%, the nega-
tive predictive value was 98.9%, and specificity was 51.4%. In patients
with a moderate score, the values were 100%, 100% and 39.6%, respec-
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tively. In patients with a high probability score, the D-dimer had values of
97.6%, 90.5% and 33.6%, respectively.
The total number of ultrasonograms performed in this study was 949; if a
strategy of serial ultrasonography was performed in all patients in this
study, we would have performed 1335 ultrasonograms. Our diagnostic
strategy led to a reduction of 29% in the need for ultrasonograms.
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Table 1. Reasons for exclusion in 75 patients.
Reason for exclusion N  
Pregnancy 1  
Previous deep venous thrombosis in the ipsilateral leg without 6
documentation of recanalization 
Concomitant clinical suspicion of pulmonary embolism 3  
The use of unfractionated heparin, low-molecular-weight heparin 50
or any form of oral anticoagulant in the past month 
Geographic impossibility for follow-up 3  
Life expectancy < 3 months 1  
No informed consent obtained 11 
(8 refused and 3 were mentally incapable of signing). 
Table 2. Prevalence of venous thromboembolism according to D-dimer result 
and pretest clinical probability score. Values are reported as number 
(percentage;95% confidence intervals).
Group VTE during follow up, Overall VTE,
n (%) n (%; 95% CI) n (%; 95% CI)  
Normal D-dimer 176 (22%) 1 (0.6%;0.02-3.1) 1 (0.6%;0.02-3.1)
and non-high score 
Normal D-dimer 39 (5%) 1 (2.8%;0.07-14.5) 4 (10.3%;2.9-24.2) 
and high score  
Normal D-dimer 215 (26%) 2 (0.9%;0.1-3.4%) 5 (2.3%;0.8-5.3%)  
Abnormal D-dimer 597 (74%) 6 (2.1%;0.8-4.4) 312 (52.3%;48.3-56.3)  
Total 812 (100%) 8 (1.6%;0.7-3.1) 317 (39.0%;35.7-42.4) 
VTE indicates venous thromboembolism and includes deep venous thrombosis and
pulmonary embolism
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DISCUSSION
This study indicates that it is relatively safe to withhold anticoagulation in
outpatients suspected of having deep venous thrombosis who have a nor-
mal D-dimer test and a non-high pretest clinical probability score. This
approach will reduce the need for compression ultrasonography. The role of
the pretest clinical probability score and/or the D-dimer concentration in
the diagnostic management of deep venous thrombosis has been the
objective of many different studies (4-14;16;17). All suggested diagnostic
regimens may not exceed the failure rate (percentage of missed deep
venous thrombosis) of 0.6% and 0.7% that have been reported in 2 land-
mark studies on the safety of serial ultrasonography (1;2). The failure rate
of 0.6% (CI 0.02-3.1%) in our study for patients with a non-high pretest
clinical probability score and a normal D-dimer concentration is comparable
with the studies in which serial ultrasonography has been used. Therefore,
we conclude that this regimen can replace serial ultrasonography in this
subgroup of patients with suspected deep venous thrombosis.
A part of the follow-up in our patients was provided by their general practi-
tioner. In The Netherlands, patients see their general practitioner on a regu-
lar basis and the general practitioner provides follow-up of their patients in
many diseases. In case of hospitalization, the general practitioner will
always be notified. At 3 months, patients were seen by a physician in one
of the participating institutes or by their general practitioner or they were
contacted by telephone by a physician in one of the participating institutes.
If a telephone contact revealed continues complaints of the leg, patients
were seen by their general practitioner or a physician. A likewise method of
follow-up has also been used in other management studies on the diagno-
sis of venous thromboembolism (5;18).
The prevalence of deep venous thrombosis in our study population was rel-
atively high (39%), especially compared with other recent studies (1;2;5-
7;14;16;17). In our institutes, this prevalence has been that high for several
years. Since the participating centers in this study are the only institutes for
diagnosing thrombosis in the region and because we have used consecutive
patients, we do not believe that this high prevalence is due to some kind of
bias. A possible explanation for this prevalence might be the referral pattern
of the general practitioner. Despite this high prevalence, exclusion of deep
venous thrombosis without performing an ultrasonography was possible in
22% of the patients. The need for ultrasonography in the whole study pop-
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ulation was reduced by approximately 30%, which means an economical
advantage and less inconvenience for patients and radiology staffs. Our
results also open the possibility for general practitioners to rule out deep
venous thrombosis in a substantial number of patients without presenting
those patients to the emergence wards.
Where previous reports excluded deep venous thrombosis using the combi-
nation of a normal D-dimer concentration and only a low pretest clinical
probability score (16;17), we show that deep venous thrombosis can also
be excluded in patients with a normal D-dimer concentration and a low and
moderate pretest clinical probability score. However, a D-dimer assay with a
high sensitivity is an important prerequisite in our strategy. Because the sen-
sitivity of the D-dimer assay in previous reports (using the SimpliRed D-
dimer assay) was only 85%, one needs to rely more extensively on the
pretest clinical probability score for a safe exclusion of deep venous throm-
bosis. However, due to the probability of an alternative diagnosis, this score
is highly subjective and shows large interobserver variability (19). The D-
dimer in our study had a sensitivity of 98.4% and a negative predictive
value of 97.7%. For exclusion of deep venous thrombosis in patients with a
non-high pretest clinical probability score and a normal D-dimer concentra-
tion, we recommend the use of a D-dimer assay with at least a sensitivity
and negative predictive value as high as the one used in the present study.
Leaving out the pretest clinical probability score from our strategy, would
have led to an increase in the percentage of missed venous thromboem-
bolism from 0.6% (95% CI: 0.02-3.1%) to 2.3% (95% CI: 0.8-5.3%) in
patients with a normal D-dimer concentration. Because of the small number
of missed thromboembolic processes, however, the confidence intervals
overlap. However, this possible additional value of a simple pretest clinical
probability score was achieved despite the fact that it was performed by
more than 20 junior residents in 4 different hospitals. Therefore, we recom-
mend using the combination of the pretest clinical probability score and a
D-dimer test in stead of using the D-dimer alone to exclude deep venous
thrombosis, as suggested by some authors (11). The use of the pretest clini-
cal probability score had only a limited effect on the total number of
patients in whom serial ultrasonography can be avoided: 39 of the 215
patients (18.1%) with a normal D-dimer concentration underwent a single
ultrasonogram because of a high pretest clinical probability.
The overall failure rate of the diagnostic strategy in our study was 1.6%
(95% CI: 0.7-3.1%). In the patients in our study in whom serial ultrasonog-
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raphy was performed, the failure rate was 2.1% (95% CI: 0.8-4.4%). This
higher percentage can be explained by the fact that only patients with a
positive D-dimer assay and, therefore, a higher a priori chance of having
deep venous thrombosis underwent serial ultrasonography. 
In conclusion, the combination of a non-high pretest clinical probability
score and a normal D-dimer concentration is a safe strategy to rule out
deep venous thrombosis without performing ultrasonography in sympto-
matic outpatients. The need for ultrasonography can be reduced by
approximately 30% using this strategy.
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The usefulness of five D-dimer assays in
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SUMMARY
BACKGROUND D-dimer measurement is a promising tool in the exclusion of
venous thrombosis. New D-dimer assays have been introduced, but need
clinical validation.
Our objective was to evaluate the clinical usefulness of four relatively new
D-dimer assays and a classical ELISA in outpatients suspected for deep
venous thrombosis.
METHODS In 537 patients, participants in a large prospective management
study using a clinical probability score and a D-dimer measurement (Tina-
quant®), additional samples were taken for D-dimer measurement using
the Asserachrom  ELISA®, the VIDAS New®, the STA-LIA® and the
Miniquant® assay. Performances of each test were calculated using clinical
data during a 3-months follow-up.
RESULTS Thrombosis was detected in 224 patients (42%). The area under
the ROC curve was significantly higher for the Tina-quant® as compared to
the other assays. Using standard cut-off values, sensitivity, negative predic-
tive value (NPV) and specificity of the Asserachrom® were 97, 94 and 33%
respectively. For the VIDAS New®, values were 100, 96 and 8% respective-
ly. The Tina-quant® showed values of 99, 98 and 41% respectively and the
STA-LIA® 98, 95 and 32%. Values for the Miniquant® were 95, 
94 and 52%.
CONCLUSIONS The D-dimer assays in our study all show a high sensitivity and
negative predictive value, but none of the assays reached a NPV of > 98%
at standard cut-off values. D-dimer assays with a low specificity still neces-
sitate additional diagnostic tests in the majority of the patients.
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INTRODUCTION
Measurement of the concentration of D-dimers is a promising tool in the
non-invasive diagnostic management of patients suspected for having deep
venous thrombosis (DVT). Retrospective analyses show a high sensitivity
and negative predictive value of D-dimer for the exclusion of venous
thromboembolism (VTE) (1-13). Two management studies have proven the
safety of withholding anticoagulants in patients with a normal D-dimer and
a normal initial ultrasonography (14;15). Various combinations of pretest
clinical probability scores and a normal D-dimer test or even a normal D-
dimer alone have been suggested to be accurate enough for the exclusion
of VTE (8;16-19). However, the choice for a diagnostic management strate-
gy depends largely upon the reliability of the D-dimer test.
Many D-dimer assays are available. The classical enzyme linked
immunosorbent assays (ELISA) are considered to be the golden standard in
determining D-dimer (1;2;4-7;9;13;20;21), but they are time-consuming
and not suitable for emergency use. The early latex assays have too little
sensitivity to be used in clinical practice (1;22) and are replaced by newer
latex assays with improved sensitivity and negative predictive value
(5;6;10;12;13;16;17;23-25).
The negative predictive value and the sensitivity of the D-dimer assay re-
present its safety in the exclusion of thrombosis in case of a normal D-
dimer. The specificity reflects its clinical usefulness from an economical
point of view. A low specificity, which is the result of a lot of false-positive
test results, still implies additional diagnostic procedures in the majority of
the patients.
The purpose of this study is to evaluate the accuracy in terms of sensitivity
and negative predictive value and the clinical usefulness in terms of speci-
ficity of four relatively new different D-dimer assays (VIDAS New®, Tina-
quant®, STA-LIA® and Miniquant®) and a classical ELISA in symptomatic
outpatients suspected for DVT. 
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PATIENTS AND METHODS
Patients
In total, 537 eligible patients entered the current study. Exclusion criteria
were pregnancy, previous deep venous thrombosis in the ipsilateral leg
without documentation of recanalisation, a concomitant clinical suspicion of
pulmonary embolism (PE), the use of unfractionated heparin, low molecular
weight heparin or any form of oral anticoagulant in the past month, geo-
graphic impossibility for follow-up and life expectancy less than 3 months.
The patients participated in a prospective multi-centre cohort study in out-
patients with suspected DVT(26) and belonged to two of the four partici-
pating centres. Patients were categorized according to their D-dimer
concentration (using the Tina-quant® D-dimer assay) and their clinical
probability score, according to Wells et al (27). In patients with a normal D-
dimer concentration and a non-high clinical score, no further testing was
done. Patients with a normal D-dimer concentration and a high clinical
score underwent a single compression ultrasonography (CUS). In case of an
abnormal D-dimer concentration, serial CUS was performed. Primary out-
come was the development of venous thromboembolism (DVT or PE) dur-
ing a 3-months follow-up period. 
Methods
D-dimer concentration was measured immediately using the Tina-quant®
D-dimer assay (Roche, Mannheim, Germany), which is a fully automated
quantitative immunoturbidimetric latex assay adapted for the Integra 70°C
(Roche, Mannheim, Germany). Additional samples were taken within 2
hours of presentation and frozen at -70oC until further study analysis. The
mean storage duration was 724 days (range 75-1296). The other D-dimer
determinations were done using the Asserachrom® ELISA (Diagnostica
Stago, Asnière, France), the VIDAS D-dimer New® ELISA (bioMerieux,
Marcy l’Etoile, France), the STA-LIA® fully automated quantitative
immunoturbidimetric latex assay measured with the STA-R® (Diagnostica
Stago, Asnière, France) and the Miniquant® fully automated quantitative
immunoturbidimetric latex assay measured with the Miniquant™-1
analyser (Biopool, Umeå, Sweden). All D-dimer assays were performed
according to the manufacturer’s instructions by technicians who were
unaware of the clinical outcomes of the patients. Test results for all D-dimer
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assays but the Miniquant® are reported as fibrin equivalent units (FEU)
mg/L; results of the Miniquant® are reported as D-dimer equivalent units in
mg/L. The cut-off value as recommended by the manufacturers was 0.5
FEU mg/L for the Asserachrom®, the VIDAS New®, the Tina-quant® and
the STA-LIA® D-dimer assays, and 0.25 mg/L for the Miniquant® assay.
For detection of DVT, ultrasonography using real-time B-mode with com-
pression was done with a 7.5 MHz and/or a 5.0 MHz transducer. Two areas
of the leg were examined: the common femoral vein at the inguinal liga-
ment and the popliteal vein at the knee-joint line traced down to the point
of the trifurcation of the calf veins. Veins were scanned in the transverse
plane only. Lack of compressibility was the sole criterion for an abnormal
result; a vein was considered fully compressible if no residual lumen was
seen.
If a patient was suspected for PE after entering the prospective manage-
ment study, a ventilation-perfusion scintigraphy was performed using rou-
tine methods. A normal scintigraphy ruled out PE, where a high probability
scan confirmed the diagnosis. An intermediate probability scintigraphy was
followed by pulmonary angiography.
Statistics
Sensitivity, negative predictive value (NPV) and specificity of the five D-
dimer assays were calculated in relation to the results of the clinical out-
comes, i.e. having venous thromboembolism at presentation or during
follow-up. For calculation of 95% confidence intervals (CI), the exact bino-
mial method was used. The Fisher’s exact test was used for comparison of
the sensitivity, NPV and specificity between the D-dimer assays. Receiver
Operator Characteristics (ROC) curves were constructed by plotting sensi-
tivity (true positive fraction) versus 1-specificity (false positive fraction)
using Analyse-it® Software for Microsoft Excel (Leeds, United Kingdom).
The area under the curve (AUC) was then calculated and compared using
the Hanley and McNeil method (28). Agreement between two methods to
classify a patient having a negative or positive test result was estimated by
calculation of the kappa coefficient: a value of > 0.81 represents an excel-
lent concordance, 0.80-0.61 a good concordance, 0.60-0.41 a moderate
concordance, 0.40-0.21 a mediocre concordance, 0.20-0 a poor concor-
dance and < 0 very poor concordance (29).
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RESULTS
The study population consisted of 537 patients. VTE was diagnosed in 224
patients (prevalence 42%): 210 patients had DVT at presentation, 11
patients had DVT detected by the second CUS, and three developed VTE
during follow-up (one DVT and two PE). Both cases of PE were detected by
ventilation-perfusion scintigraphy.
Figure 1 shows the ROC curves displaying sensitivity and specificity for the
different D-dimer assays at different cut-off levels. Using the Asserachrom®
ELISA as the reference test, the AUC of the VIDAS New®, STA-LIA® and
Miniquant® assays were not different (p=0.6, p=0.8 and p=0.1 respective-
ly) (Table 1). The AUC of the Tina-quant® was significantly higher com-
pared with the other assays; p=0.003 for comparison with the
Asserachrom®, p=0.004 with the VIDAS New®, p<0.0001 with the STA-
LIA® and p=0.01 with the Miniquant®.
The performance of the different D-dimer assays is given in Table 2, show-
ing sensitivity, NPV and specificity with 95% confidence intervals according
to different cut-off values for each assay. Given the cut-off values as recom-
mended by the manufacturers, all D-dimer assays had a sensitivity of 95%
or higher and a NPV of 94% or higher. The highest NPV (98%) was seen
with the Tina-quant®; this was not significantly different as compared to
the Asserachrom® (p=0.08), the VIDAS New® (p=0.4) and the STA-LIA®
(p=0.2), but higher as compared to the Miniquant® (p=0.047). The highest
sensitivity (100%) was seen with the VIDAS New® assay: this was not sta-
tistically different as compared to the Asserachrom® (p=0.07), the Tina-
quant® (p=1.0) and the STA-LIA® (p=0.2), but higher as compared to the
Miniquant® (p=0.006). Sensitivity of the Miniquant® (95%) was lower as
compared to the Tina-quant® (p=0.02). By changing the cut-off values,
only in the Tina-quant® a NPV of 100% could be reached. Slight (not sta-
tistically significant) improvements of the NPV were seen in the
Asserachrom® and STA-LIA® assays by lowering the cut-off values, but
they led to significant reductions in specificity. A low specificity was seen for
the VIDAS New® D-dimer assay: its specificity of 8% was lower than the
other D-dimer assays that showed values of 32-52% (p<0.0001 when
compared to the Asserachrom®). The number of patients with a negative
VIDAS New® D-dimer test result was 27/537 as compared to 110/537
negative Asserachrom® tests (p<0.0001), 131/537 negative Tina-quant®
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tests (p<0.0001), 106/537 negative STA-LIA® tests (p<0.0001) and
174/537 negative Miniquant® tests (p<0.0001). 
Table 3 shows the kappa coefficients between the 5 D-dimer assays. The
concordance of the Asserachrom® with the Tina-quant® and the STA-LIA®
is good, with the Miniquant® moderate and with the VIDAS New®
mediocre. The concordance of the VIDAS New® with the other D-dimer
assays was mediocre or worse. Concordance between the Tina-quant®,
STA-LIA® and Miniquant® was good.
Figure 1. ROC curve analysis of the accuracy of measurement of plasma 
D-dimer concentrations using different D-dimer assays.
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Table 1. Comparison of the area under ROC curves (AUC) for the 5 D-dimer assays,
reported as p-values.
AUC (95%CI) VIDAS New® Tina-quant® STA-LIA® Miniquant®
Asserachrom® 0.879 (0.850-0.908) 0.6 0.003 0.8 0.1  
VIDAS New® 0.887 (0.859-0.916) 0.004 0.7 0.2  
Tina-quant® 0.922 (0.900-0.945)   <0.0001 0.01  
STA-LIA® 0.883 (0.854-0.911)    0.07  
Miniquant® 0.902 (0.874-0.930)
Table 3. Kappa coefficients between the 5 D-dimer assays.,
VIDAS New® Tina-quant® STA-LIA® Miniquant®
Asserachrom® 0.33 0.63 0.70 0.59  
VIDAS New® 0.24 0.31 0.18  
Tina-quant® 0.70 0.72  
STA-LIA® 0.62 
For the calculation of the accuracy indices, quantitative D-dimer results lower than the
cut-off value were considered to be negative. Cut-off values for the Asserachrom®,
VIDAS New®, Tina-quant® and STA-LIA® were 0.5 FEU mg/L. The cut-off value for
the Miniquant® was 0.25 D-dimer equivalent units mg/L.
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Table 2. Clinical performance of the different D-dimer assays. Values are 
reported as percentage and their 95% confidence intervals. Cut-off 
values as recommended by the manufacturers have been given in bold.
D-dimer assay Cut-off value Sensitivity  Negative Specificity
predictive
value    
Asserachrom® 1.0 FEU mg/L 88 (84-93) 89 (85-93) 68 (63-73)
0.5 FEU mg/L 97 (94-99) 94 (87-97) 33 (28-38)
0.4 FEU mg/L 99 (96-100) 96 (89-99) 24 (20-29)
0.3 FEU mg/L 99 (97-100) 96 (85-99) 13 (10-17)
0.2 FEU mg/L 100 (98-100) 95 (75-100) 6 (4-9)  
VIDAS New® 1.0 FEU mg/L 98 (96-100) 96 (90-99) 29 (24-34)
0.5 FEU mg/L 100 (98-100) 96 (81-100) 8 (6-12) 
0.4 FEU mg/L 100 (98-100) 93 (66-100) 4 (2-7)   
0.3 FEU mg/L 100 (98-100) 88 (47-100) 2 (1-5)   
0.2 FEU mg/L 100 (98-100) 0 (0-100) 0 (0-12)  
Tina-quant® 1.0 FEU mg/L 93 (89-96) 94 (90-96) 70 (65-75)   
0.5 FEU mg/L 99 (97-100) 98 (95-100) 41 (36-47)
0.4 FEU mg/L 100 (98-100) 99 (94-100) 31 (26-36)   
0.3 FEU mg/L 100 (98-100) 100 (94-100) 18 (14-22)   
0.2 FEU mg/L 100 (98-100) 100 (74-100) 4 (2-7)  
STA-LIA® 1.0 FEU mg/L 94 (90-97) 93 (89-96) 60 (55-66)   
0.5 FEU mg/L 98 (95-99) 95 (89-99) 32 (27-37)   
0.4 FEU mg/L 99 (97-100) 98 (91-100) 25 (20-30)   
0.3 FEU mg/L 100 (98-100) 98 (89-100) 15 (11-19)   
0.2 FEU mg/L 100 (98-100) - 0 (0-1)  
Miniquant® 0.5   mg/L 90 (86-94) 91 (86-94) 72 (67-77)
0.25 mg/L 95 (91-98) 94 (89-97) 52 (47-58)   
0.2   mg/L 96 (93-98) 94 (88-97) 43 (37-48)
0.15 mg/L 95 (91-97) 93 (87-97) 35 (29-40)   
0.1   mg/L 98 (96-100) 93 (83-98) 17 (13-21)  
73
Comparison of D-dimer assays
DISCUSSION
The diagnostic strategy in patients suspected for DVT or PE is being chal-
lenged by the development of highly sensitive D-dimers and the revival of
the pretest clinical probability score. Recent studies have demonstrated the
safety of withholding anticoagulant treatment in patients with a normal 
D-dimer and a normal single ultrasound (14;15). Even the combination of a
low clinical score and a normal D-dimer concentration can be considered a
safe strategy to exclude thrombosis and to withhold anticoagulant therapy
in patients suspected for venous thromboembolism (8;15-17;19;26;30-32).
When trying to replace accepted strategies like venography or serial ultra-
sound, their failure rates of, respectively, 1.3% (33) and 0.6-0.7% (34;35)
may not be exceeded by the new diagnostic strategy. Therefore, a highly
sensitive D-dimer test is mandatory for the exclusion of thrombosis in every
new diagnostic strategy. Differences between D-dimer assays are thought
to be caused by antibody specificity, especially concerning the preference
for high- or low molecular weight fibrin derivates and for crosslinked and
non-crosslinked fibrin derivates (36). Other causes of discrepancies
between D-dimer assays are time-dependence of neo-epitope expression in
the course of fibrin formation and dissolution, assay format, purity or het-
erogeneity of the calibrator, matrix effects of plasma on epitope presenta-
tion and interference by irrelevant analytes (37).
In our study, ROC curve analysis showed a significantly higher AUC for the
Tina-quant® D-dimer assay as compared to the other four assays. At stan-
dard cut-off values, the Tina-quant® also had the highest NPV with 98%
(although not statistically different), with a high sensitivity of 99%. The
performance of the Tina-quant® in our study was comparable with previous
reports (1;5;13). Using standard cut-off values, the Miniquant® reached a
sensitivity of 95% with a NPV of 94%, which is comparable with previous
reports (38-40). It had significant lower values of sensitivity and NPV as
compared to the Tina-quant® and a significant lower sensitivity as com-
pared to the VIDAS New®. Results of the STA-LIA® assay showed a high
sensitivity of 98% and NPV of 95%. This is higher than a previous report
that found a sensitivity of 89% and NPV of 86% (41) but comparable with
other reports (42-44). The VIDAS New® had an excellent sensitivity of
100% and a NPV of 96%, which was better than a previous report (45) but
comparable with a study from de Moerloose et al (46).
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It is well known that the D-dimer tests have positive results in case of vari-
ous co-morbid conditions, such as infections and malignancy. Due to these
frequent false-positive test results, the specificity of the D-dimer is low. It is
the specificity that determines the usefulness of the D-dimer as an exclu-
sion criterion for thrombosis. A low specificity of a D-dimer implies that
CUS will still be necessary in the majority of the patients. Although the sen-
sitivity and NPV of the VIDAS New® were high, a remarkably low specifici-
ty of 8% was found. This low specificity is in disagreement with two
previous reports on the VIDAS New® (45;46) that found a specificity of
42% and 33% respectively at the same cut-off level. Furthermore, the
kappa coefficients of the VIDAS New® compared to the other four assays
were mediocre to poor. This is in disagreement with the kappa coefficients
for the original VIDAS compared to the STA-LIA®, Asserachrom® and Tina-
quant® as found by van der Graaf et al (13). As the VIDAS New® assay is
fully automated and not dependent on technician skills, it is not likely that
variables in the analytic process have lead to the large number of false-pos-
itive results in our study. A previous report has seen no effect of transporta-
tion or storage at room temperature on the results of the VIDAS® D-dimer
assay (47). We showed recently that freezing of samples or type of chemi-
cal analyser had no influence on D-dimer concentration (48). A consider-
able improvement of the performance of the VIDAS New® was achieved
after raising the cut-off level to 1.0 FEU mg/L, resulting in a sensitivity of
98%, a NPV of 96%, and a specificity of 29%.
The D-dimer assays in our study all showed generally high sensitivity and
NPV. In general, the sensitivity could be improved by lowering the cut-off
values, but the subsequent decrease in specificity makes the assays less use-
ful in clinical practice. Despite changes in cut-off values none of the tests
reached a NPV of > 98%, except for the Tina-quant®. Using standard cut-
off values, none of the tests reached a NPV of > 98%. When the use of 
D-dimer is restricted to patients with a low clinical probability score only, it
has been shown for the SimpliRed® and Tina-quant® assay that the NPV of
the D-dimer assay will further increase (18;26;30). It is therefore to be
expected that the combination of a clinical probability score and the other
D-dimer tests from our study will also increase the NPV and be a safe strat-
egy to exclude DVT in outpatients.
In conclusion, the D-dimer assays in our study all show a high sensitivity
and negative predictive value. However, using standard cut-off values,
none of the assays reached a NPV of > 98%. For exclusion of DVT, we
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therefore recommend combining the D-dimer assay with other non-inva-
sive tests in order to reach failure rates less than 1.0%. The use of D-dimer
assays with a very low specificity might not be worthwhile from an eco-
nomical point of view, as a positive test will necessitate additional testing in
the majority of the patients.
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CHAPTER  7
Low molecular weight heparin is equally
effective as unfractionated heparin in
reducing coagulation activity and 
perfusion abnormalities during the 
early treatment of pulmonary embolism
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F.J.L.M. Haas3, F. Verzijlbergen4, H.K. Nieuwenhuis5, 
D.H. Biesma1.
Departments of 1Internal Medicine, 2Pulmonology, 3Clinical Chemistry and
4Nuclear Medicine St. Antonius Hospital Nieuwegein, and 5Department of
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SUMMARY
BACKGROUND: Little is known about differences between UFH and LMWH
on coagulation activity during treatment for pulmonary embolism. The
objective of this study was to compare UFH and LMWH in the early treat-
ment of pulmonary embolism in terms of control of coagulation markers
and perfusion abnormalities.
METHODS: 37 patients with acute pulmonary embolism were randomised to
receive intravenous UFH or subcutaneous dalteparin, both together with
acenocoumarol. Daily samples were obtained for measurement of thrombin
generation (fragments 1+2, TAT-complexes and fibrin monomers) and fibri-
nolysis (D-dimer concentrations and clot lysis times). Ventilation-perfusion
scintigraphies were performed from which the percentage-of-vascular-
obstruction scores (PVOs) were calculated at day 0 (PVOsD0) and day 5
(PVOsD5).
RESULTS: The INR was therapeutic in both groups at day 3. At day 3, anti-Xa
levels were 0.21 IU/ml in the UFH group (n=19) and 0.29 IU/ml in the
LMWH group (n=18) (p=0.1). F1+2 and TAT-complexes rapidly normalised
without differences between the groups (p=0.5 and p=0.4 resp.). Fibrin
monomer levels did not decrease, and showed an increase in the UFH
group from day 3 (p<0.05 for differences between the groups). D-dimer
levels decreased over time, without differences between the groups
(p=0.6). Clot lysis times were shorter in the UFH group (p<0.05). The
PVOsD0 and PVOsD5 were not different (p=0.5 and p=0.8 resp), but the
decrease of the PVOs over time was higher in the LMWH group (p=0.04). 
CONCLUSION: LMWH is at least equally effective as UFH in reducing coagu-
lation activity and perfusion abnormalities in the early treatment of pul-
monary embolism.
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INTRODUCTION
Intravenous administration of unfractionated heparin (UFH) has proven its
efficacy in the early treatment of venous thromboembolism (1-3). The pur-
pose of using heparin in the treatment of thrombosis is to inhibit thrombin
generation. The use of UFH, however, has several inconveniences.
Intravenous administration of UFH requires hospitalisation and frequent
monitoring of the activated partial thromboplastin time (aPTT) for optimal
dose-adjustment. Low molecular weight heparin (LMWH) has the advan-
tage of a subcutaneous administration route, more stable plasma heparin
concentrations, the absence of the need for monitoring and a lower inci-
dence of heparin-induced thrombocytopenia (4). Treatment of deep venous
thrombosis of the leg with LMWH is considered to be equally safe as UFH
when looking at clinical outcomes (5-20). LMWH also appears to be safe in
the treatment of pulmonary embolism from a clinical point of view
(10;16;21-24). Less agreement exists about the effect of LMWH versus
UFH in reducing coagulation activity in venous thrombosis. Some studies
report a more rapid decrease in coagulation activity by UFH as compared to
LMWH (25;26), whereas others find the opposite (27;28) or no differences
(29-31). These studies mainly concern patients with deep venous thrombo-
sis or healthy donors. The effect of LMWH versus UFH on early changes in
haemostatic markers in patients with pulmonary embolism has not yet been
studied. As many clinicians still use UFH in the treatment of pulmonary
embolism, the finding of equal or more effectiveness of LMWH on coagula-
tion markers and perfusion abnormalities might further support the use of
LMWH in the initial treatment of pulmonary embolism.
The purpose of this study is to compare UFH and LMWH in their capacity
to inhibit thrombin generation in the early treatment of pulmonary
embolism by measuring prothrombin fragments 1+2 (F1+2), thrombin-
antithrombin complexes (TAT) and fibrin monomers. Secondly, we compare
UFH and LMWH in their effects on fibrinolysis by measuring D-dimer con-
centrations and clot lysis times. Finally, we compare UFH and LMWH in
terms of changes in perfusion abnormalities during the early days of treat-
ment for pulmonary embolism. 
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PATIENTS AND METHODS
Study design
This was a randomised, non-blinded study where continuous infusion of
dose adjusted unfractionated heparin was compared to a once daily subcu-
taneous injection of dalteparin in terms of changes in coagulation markers
and changes in perfusion abnormalities. Informed consent was obtained
from all participating patients and the medical ethical committee of our
institute approved the study protocol. The primary endpoint of this study
was the time course of different coagulation and fibrinolytic markers in the
two heparin regimens. The secondary endpoint was the evaluation of
changes in perfusion abnormalities during the early treatment with the two
heparins.
Patients and study protocol
Patients with proven symptomatic pulmonary embolism (as described later)
were eligible for this study. Exclusion criteria were active malignancy
(defined as currently receiving any treatment for cancer or documented
recurrent or metastatic disease), recent surgery or large trauma in the past
month, the use of any form of anticoagulant in the past month, pregnancy,
a history of heparin-induced thrombocytopenia and the presence of a con-
traindication for anticoagulation. Patients were randomised to receive UFH
or LMWH (dalteparin). UFH was given within 1 hour after diagnosis as an
intravenous bolus of 5000 IU, followed by continuous infusion, starting
with 25000 IU/d. Dosage adjustment was made by monitoring the ratio of
the activated partial thromboplastin time (aPTT). The first aPTT ratio was
measured 6 hours after the start of UFH and was followed by monitoring
twice a day with a target range of 2.0-3.5. In patients who were ran-
domised for LMWH, dalteparin was given through a subcutaneous injection
within 1 hour after diagnosis and after that once a day at 17h00. Dosages
of dalteparin were body weight-adjusted: < 55 kg: 10.000 IU; 55-65 kg:
12.500 IU; 65-85 kg: 15.000 IU; > 85 kg: 18.000 IU. Within 24 hours of
the start of the study, oral coumarin derivates were started (aceno-
coumarol). Treatment with UFH or dalteparin was stopped when the
International Normalized Ratio (INR) was > 2.0 on two consecutive days
with a minimum duration of five days.
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Laboratory assessments
Before the start of any anticoagulant therapy, and following daily between
08h00 and 09h00 the next consecutive 5 days, blood was drawn. The day
of presentation and before treatment was started, was considered to be day
0. The INR was measured daily using the Hepato Quick® (Diagnostica
Stago, Asnière, France) and the aPTT using the CephotestTM (Axis-Shield
PoC AS, Oslo, Norway). Extra samples were stored and frozen at –70oC
until further assessment. Anti-Xa levels were measured at day 3 using the
Staclot® Heparin (Diagnostica Stago, Asnière, France).
Thrombin generation was estimated by measurement of prothrombin frag-
ments 1+2 (F1+2) using the ELISA Enzygnost® F1+2 (Dade Behring,
Schwalbach, Germany) with normal values 0.4-1.1 nmol/l, thrombin-
antithrombin complexes (TAT) using the ELISA Enzygnost® TAT micro
(Dade Behring, Schwalbach, Germany) with normal values 1.0-4.1 µg/l and
fibrin monomers using Berichrom® FM (Dade Behring, Schwalbach,
Germany) with normal values <3.4-14.5 mg/l.
Effects on fibrinolysis were estimated by measuring D-dimer concentration
using the ELISA Asserachrom® (Diagnostica Stago, Asnière, France) with
normal values < 500 µg/ml Fibrin Equivalent Units (FEU) and plasma clot
lysis times using previously described methods (32;33), where lysis of a tis-
sue-factor induced clot by exogenous t-PA was studied by monitoring
changes in turbidity during clot formation and subsequent lysis. The contri-
bution of thrombin activatable fibrinolysis inhibitor (TAFI) to the clot lysis
time was assessed after addition of 25 µg/ml carboxypeptase inhibitor (CPI,
Calbiochem, La Jolla, CA) to the plasma, which is a specific inhibitor of acti-
vated TAFI (34).
Laboratory assessments were done by skilled personnel who were unaware
of the treatment regimens.
Diagnosis of pulmonary embolism
In all patients, a ventilation-perfusion scintigraphy was performed at pres-
entation (day 0). Lung scans were performed in 4 standard views: anterior,
posterior and right and left posterior oblique. Additional right and left later-
al views were performed at indication. For interpretation of the scans, Hull’s
criteria were used (35), as well as a lung segment reference chart (36). A
normal scintigraphy ruled out pulmonary embolism, where a high probabili-
ty scan confirmed the diagnosis. An intermediate probability scintigraphy
was followed by pulmonary angiography. During this angiography, a stan-
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dard intravenous dose of 5.000 IU UFH was given. The ventilation-perfu-
sion scintigraphy was repeated at day 5. These results were compared with
the results obtained at day 0 by two nuclear specialists who were unaware
of the treatment regimens. The percentage-of-vascular-obstruction score
(PVOs), as described previously (37;38), was calculated at day 0 (PVOsD0)
and at day 5 (PVOsD5).
Statistics
For comparison of baseline characteristics between the two groups, the
Fisher’s exact test and the Mann-Whitney U test were used with two-tailed
p-values. We used the repeated measurement MANOVA for comparison of
groups over time with the SAS software (SAS version 8.2, Cary, NC, USA).
The Mann-Whitney U test with two-tailed p-values was used to compare
daily values between the groups using SPSS software (SPSS version 10.0.5,
Chicago, USA). Bivariate correlation between laboratory values and PVOs
was calculated using SPSS software.
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RESULTS
Forty patients with proven pulmonary embolism were included in this study.
In three patients, more than one sample was missing; these 3 patients were
excluded from further analysis. Of the remaining 37 patients, 19 patients
received UFH and 18 patients received LMWH. For baseline characteristics,
see Table 1. The two groups were comparable considering gender, the
PVOs and the number of angiographies performed. Patients receiving dal-
teparin were of older age. Except for F1+2 levels, which were higher in the
LMWH group, the coagulation and fibrinolytic markers were comparable.
The INR reached therapeutic values in both groups at day 3: the median in
the LMWH group was 2.3 and in the UFH group 2.1 (p=0.4), the means
were 2.4 ± 0.8 and 2.1 ± 0.8. The mean aPTT ratio in the UFH group after
24 hours was 2.0 ± 0.7, where 8/19 (42%) had values > 2.0. At day 3,
15/19 (79%) had values > 2.0, at day 4 17/19 (89%) and at day 5 all
patients had an aPTT ratio > 2.0. Anti-Xa levels at day 3 were 0.29 ± 0.15
IU/ml in the LMWH group and 0.21 ± 0.1 IU/ml in the UFH group (p=0.1).
No bleeding complications were observed in the total study population.
Table 1. Baseline characteristics in patients with pulmonary embolism initially 
treated with intravenous unfractionated heparin or subcutaneous 
dalteparin. Values are reported as median, unless indicated. (F1+2 = 
fragments 1+2, TAT = thrombin-antithrombin, FEU= Fibrin Equivalent 
Units, PVOs = percentage-of-vascular-obstruction score)
Unfractionated heparin Dalteparin P-value
N = 19 N = 18
Women/men (n) 12/7 7/11 0.2  
Age (median;range) 46 (28-74) 60 (30-82) 0.02  
Angiography (n) 3 3 1.0
F1+2 (nmol/l) 1.4 2.2 0.03
TAT-complexes (µg/l) 6.6 6.7 0.9  
Fibrin monomer (mg/l) 22.6 21.6 0.6  
D-dimer (µg/ml FEU) 1950 2611 0.7 
Clot lysis time (min) 52 45 0.9  
PVOs (%) 28.6 22.9 0.5 
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Evaluation of thrombin generation
The levels of F1+2 decreased over time in the total group (p<0.0001)
(Figure 1a). Baseline values were higher in the LMWH group as to com-
pared to the UFH group (p=0.03). After treatment, F1+2 levels normalised
rapidly in both groups. No differences were seen at day 1 (p=0.3), day 2
(p=0.052), day 3 (p=0.2), day 4 (p=0.4) and day 5 (p=0.2).
A rapid normalisation of TAT complexes was seen in both groups compared
to baseline values (p=0.02) (Figure 1b). After day 1, the levels of TAT com-
plexes remained normal. Between the groups, there was no difference over
time (p=0.5). Comparison of daily values between the groups showed no
significant differences (p=0.9 at day 0, p=0.3 at day 1, p=1.0 at day 2,
p=0.4 at day 3, p=0.4 at day 4 and p=0.3 at day 5).
Fibrin monomer levels did not decrease to normal values during treatment
in both heparin regimens. They remained stable in the LMWH group, but
increased again in the UFH group. Differences were significant at day 3
(p=0.04), day 4 (p=0.04) and day 5 (p=0.003) (Figure 1c).
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Figure 1. The effect of low molecular weight heparin (LMWH) and unfractionated
heparin (UFH) on thrombin generation in patients with pulmonary 
embolism. Dotted lines represent upper normal values. 
a) Fragment 1+2 levels (F1+2), b) Thrombin-antithrombin (TAT)-
complexes, c) Fibrin monomer (FM) levels
91
The TEST
Evaluation of fibrinolysis
The course of the D-dimer levels showed a significant decrease in both
groups over time (p<0.0001), but there were no differences between the
two groups over time (p=0.6) (Figure 2a). Comparing daily values, there
were no differences between the groups (p=0.7 at day 0, p=0.7 at day 1,
p=0.9 at day 2, p=1.0 at day 3, p=0.8 at day4 and p=0.6 at day 5).
Plasma clot lysis times are shown in Figure 2b. There was a significant dif-
ference between the groups over time, with longer clot lysis times in the
LMWH group (p<0.0001). Lysis times did not differ at day 0 and 1 (p=0.9
and p=0.1 respectively), but from day 2 they were longer in the LMWH
group (p=0.003 at day 2, p<0.001 at day 3, p=0.001 at day 4 and p=0.02
at day 5).
After addition of CPI, there was a similar decrease in clot lysis times at day 0
in both groups (p=0.28). Clot lysis times between the groups were not dif-
ferent at day 0 and day 1 (p=0.052 and p=0.06 respectively), but they were
higher from day 2 in the LMWH group (p=0.007 at day 2, p=0.001 at day
3, p=0.006 at day 4 and p=0.048 at day 5). There was no additional effect
of CPI on clot lysis times after the start of UFH. In the LMWH group, CPI
resulted in shorter clot lysis times at day 0 and day 1 (p=0.001 and p=0.04
respectively), but not at day 2, 3, 4 and 5 (p=0.2, p=0.2, p=0.1 and p=0.1
respectively).
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Figure 2. The effect of low molecular weight heparin (LMWH) and unfractionated
heparin(UFH) on fibrinolysis in patients with pulmonary embolism. 
Dotted line in figure 2a represents upper normal value. 
CPI = carboxypeptase inhibitor
a) D-dimer levels, b) Clot lysis time 
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Perfusion abnormalities
Six patients did not have a second ventilation-perfusion scintigraphy at day
5 (3 in the UFH and 3 in the LMWH group). They were excluded from
PVOs analysis. In the remaining 31 patients, the median of the PVOsD0
was 28.6% in the LMWH group and 22.9% in the UFH group (p=0.5)
(Figure 3). At day 5, the values were 15.0% and 23.2% respectively
(p=0.8). In the LMWH group, there was a reduction in PVOs although not
statistically significant (p=0.09). In the UFH group, no reduction was seen
(p=0.6). Although values at day 0 and 5 did not differ statistically between
the groups, there was a significant difference in the decrease of the PVOs
over time in favour of the LMWH group (p=0.04).
There was a correlation between the PVOsD0 and the initial F1+2 levels at
presentation (p=0.009) and between the PVOsD0 and the initial D-dimer
levels at presentation (p=0.04). No correlation was found between the
PVOsD0 and other laboratory variables. There was no correlation between
the PVOsD5 and any laboratory marker at day 5.
Figure 3. Percentage-of-vascular-obstruction score (PVOs) at day 0 (PVOsD0) and
day 5 (PVOsD5) in patients with pulmonary embolism treated with low 
molecular weight heparin (LMWH) or unfractionated heparin (UFH)
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DISCUSSION
Inhibiting thrombin generation is the main purpose of treatment of venous
thrombosis with heparins. The safety of UFH and LMWH in the treatment
for venous thrombosis has been demonstrated in a number of trials (5-24).
Few data exist on the effectiveness of both heparin regimens in controlling
coagulation markers in deep venous thrombosis. A recent large report
showed the efficacy of LMWH in reducing thrombin generation at 1 and 3
weeks (39), but for pulmonary embolism no such studies have been con-
ducted.
In this study, we demonstrate that in patients with pulmonary embolism,
both UFH and LMWH immediately decrease levels of F1+2 fragments and
TAT-complexes to normal values. The decrease by UFH is in agreement with
previous reports (40,41) and the similar decrease in both heparin regimens
has been found by others (30,31). The DVTENOX trial, however, showed
more rapid decreases of TAT-complexes and F1+2 in patients treated with
enoxaparin compared to UFH (27). On the other hand, in a smaller study,
Stricker et al found the opposite (25). Some authors seek an explanation for
the differences between the studies in the degree of anticoagulation and
the moment of reaching therapeutic ranges (25;27).
Interestingly, fibrin monomer levels did not decrease in both heparin regi-
mens. In patients treated with UFH, they even showed an increase after 3
days of treatment. This might implicate that UFH inhibits fibrin formation in
a lesser extent over time than LMWH. As the increase in fibrin monomers in
UFH is seen from day 3, this cannot be explained by non-therapeutic
ranges of UFH, as therapeutic ranges were reached after 3 days. However,
anti-Xa levels in the LMWH group were higher at day 3; although this dif-
ference was not statistically significant, it might be clinically relevant. One
study reported higher anti-Xa levels and lower fibrin monomer levels during
infrainguinal bypass surgery in patients treated with LMWH compared to
UFH (42). Another explanation may be found in fibrin-bound thrombin.
After generation of fibrin, activated thrombin can bind to fibrin. This fibrin-
bound thrombin retains its procoagulant activity, but is protected from
antithrombin-induced inhibition through the formation of ternary throm-
bin-fibrin-heparin complexes (43-46). Furthermore, fibrin is a potent modu-
lator of heparin activity in vivo by inhibiting heparin-catalyzed
thrombin-antithrombin complex formation through formation of these ter-
nary complexes (47). One could postulate that the formation of this ternary
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complex might differ between UFH and LMWH and therefore might influ-
ence thrombin inactivation and subsequent fibrin formation. Indeed, Hogg
et al found that heparins with lower molecular weight are less effective in
promoting thrombin binding to fibrin polymer (48). Furthermore, during
LMWH therapy, higher antithrombin levels are maintained compared to
UFH (39,49,50). This implicates that in patients treated with LMWH, more
thrombin will be inhibited by antithrombin and less fibrin will be generated.
Although this could explain the differences in fibrin monomer levels
between UFH and LMWH in our study, the increase of fibrin monomer 
levels in the UFH group is still not clear.
The role of heparin in the enhancement of fibrinolysis is thought to be
through inhibition of thrombin-dependent generation of activated TAFI. As
a result, stabilisation of a clot by TAFI will be diminished, leading to short-
ening of clot lysis times. In our study, we found that both heparins resulted
in shorter clot lysis times after treatment. In vitro inactivation of TAFI by CPI
eliminated any further effect of heparin on clot lysis times, confirming the
findings of Lisman et al (51), that the effect of heparin on the clot lysis time
is mainly through TAFI. However, the clot lysis times were longer in the
LMWH group when compared to the UFH group (p<0.0001); this differ-
ence remained significant after inhibition of TAFI by CPI. The fact that the
lysis times in our study were shorter after treatment with UFH, independent
of TAFI activity, raises the question whether there are other factors involved
through which UFH has more influence on clot lysis times than LMWH.
Urano et al found that addition of factor Xa together with calcium shortens
clot lysis times (52). The lower anti-Xa levels in our UFH group (although
not statistically significant) might therefore be the explanation for our find-
ings. Another possibility could be the tissue-plasminogen activator (t-PA)
levels. It has been shown that heparin shortens clot lysis times through an
increase in t-PA (53). If UFH increases t-PA more than LMWH, this will
result in shorter clot lysis times. Unfortunately, we were not able to perform
these tests retrospectively.
Reports on the course of D-dimer levels during treatment with heparin and
the differences between UFH and LMWH are heterogeneous
(25,27,31,39,40). In our study, we found a decrease of D-dimer levels over
time in both groups (p<0.0001), without differences between the groups.
This implicates that LMWH has a similar effect on fibrinolysis in vivo as
UFH.
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As a clinical endpoint of our study, we calculated the PVOs before and at
the end of treatment. There was no significant difference between the
groups at day 0 and day 5. However, there was a decrease in the LMWH
group, while no decrease was seen in the UFH group (p=0.04). These find-
ings might argue in favour of LMWH as initial treatment for pulmonary
embolism. From a clinical point of view, it is of interest to be informed
about possible correlations between laboratory variables and perfusion
abnormalities. We found a correlation between F1+2 and D-dimer levels
and perfusion abnormalities, where higher levels of F1+2 or D-dimer corre-
lated with higher vascular obstruction scores. Therefore, the initial height of
F1+2 or D-dimer might give an indication of the severity of the pulmonary
embolism. This is in agreement with a previous report (54). At day 5, we
found no correlation between any laboratory value and perfusion abnor-
malities. This implicates that the coagulation and fibrinolytic markers in our
study are not suitable for clinical follow-up evaluation. 
In conclusion, LMWH (dalteparin) is at least equally effective as UFH in
reducing coagulation activity and in prohibiting further increases in perfu-
sion abnormalities in the early treatment of pulmonary embolism. Our find-
ings support the use of LMWH as initial treatment of pulmonary embolism.
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High D-dimer concentrations can predict
malignancy in patients presenting with
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SUMMARY
BACKGROUND Venous thromboembolism can be related to malignancy, but
routine screening for cancer in patients with deep venous thrombosis (DVT)
is a matter of debate.
METHODS In consecutive outpatients with proven DVT, D-dimer measure-
ment was done at presentation. Patients were followed for a median of 31
months and the occurrence of malignancy was documented. In a propor-
tion of the patients, daily measurements of D-dimers were performed for 4
consecutive days.
RESULTS Forty-nine (22%) of 218 patients with DVT had or developed can-
cer: 28 patients were known with cancer, in 8 patients cancer was discov-
ered at time of presentation with DVT and during folow-up 13 patients
developed cancer. The prevalence of cancer in patients with initial D-dimer
levels < 4000 µg/l was 16% as compared to 35% in patients with D-dimer
levels > 4000 µg/l (p=0.005). After 4 days of treatment, the prevalence of
cancer was 14% when D-dimer levels were < 4000 µg/l, compared to 46%
when they were still > 4000 µg/l (p=0.02). Of the patients with thrombosis
and cancer, 78% (38/49) was older than 60 years. D-dimer levels at age >
60 did not disciminate in the presence or absence of cancer. In younger
patients, initial D-dimer levels of < 4000 µg/l were associated with a cancer
prevalence of 3% compared to 23% at levels > 4000 µg/l (p=0.001). After
4 days of treatment, cancer prevalences were 0% and 100% in younger
patients with D-dimer levels < and > 4000 µg/l respectively (p=0.003).
CONCLUSIONS High D-dimer concentrations at presentation and persistently
high D-dimer levels during the first days of treatment are indicators of an
increased change for overt or occult forms of cancer, especially in patients
younger than 60 years.
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INTRODUCTION
The development of venous thromboembolism is associated with transient
risk factors for thrombosis like surgery or trauma, and permanent risk fac-
tors (such as factor V Leiden, the prothrombin mutation, protein C and S
deficiency, antithrombin deficiency, lupus anticoagulant and hyperhomo-
cysteinemia). Venous thromboembolism can also be related to malignancy
(1-5). The incidence of malignancy in patients with thrombosis is 7-26%
(6-10). Patients with cancer are at higher risk of developing venous throm-
boembolism, which has been observed especially in postoperative patients
with cancer and in patients receiving chemotherapy (11). 
Although several studies have tried to define clinical conditions in which
cancer is more frequent in venous thromboembolism (3,6,10,12,13), there
is still debate about routine screening for occult malignancy. It would be of
interest if certain patients with thrombosis could be identified as having an
increased risk of having malignancy. The mechanism of the hypercoagula-
ble state in cancer is complex and many markers of blood clotting activation
are disturbed (2,14,15). Increased concentrations of D-dimers, specific
markers of fibrinolysis, can be found in patients with cancer (18-19). As in
many patients suspected for venous thromboembolism a D-dimer measure-
ment is now being performed according to more recently developed diag-
nostic strategies (20-24), it is of interest to know whether the D-dimer
concentration can be used as a predictor for cancer as cause for venous
thromboembolism in these patients. 
The aim of this study is to investigate whether the initial height of the 
D-dimer level in patients with deep venous thrombosis or early changes in
D-dimer levels during treatment for deep venous thrombosis can differenti-
ate between patients with and without cancer.
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PATIENTS AND METHODS
Consecutive outpatients with proven deep venous thrombosis of the leg
were included in this study from July 1998 to October 2001. Ineligibility cri-
teria were the use of anticoagulants, pregnancy and not documented
recanalisation after a previous history of deep venous thrombosis in the
ipsilateral leg. Thrombosis was diagnosed using real-time B-mode compres-
sion ultrasonography, where lack of compressibility was the criterion for an
abnormal result; a vein was considered fully compressible if no residual
lumen was seen. In all patients, a D-dimer measurement was done using
the Tina-quant® quantitative latex assay (Roche, Mannheim, Germany) at
presentation. D-dimer values above 8000 µg/l FEU (Fibrinogen Equivalent
Units) were not diluted further and were reported as > 8000 µg/l FEU.
Treatment for thrombosis was started immediately and was given as a once
daily subcutaneous injection with a low molecular weight heparin (dal-
teparin; dose adjusted to weight). Oral acenocoumarol was started simulta-
neously. Patients were treated with dalteparin for at least 5 subsequent
days until the INR was > 2.0. We documented the presence of previously
known malignancy and the type of malignancy that was detected at the
moment of thrombosis or developed during follow-up. Data on the follow
up period were obtained by checking the medical records in the participat-
ing hospital from July 1998 to February 2002, by sending a questioner to
the patient’s general practitioner and by checking the national database
network and registry of histo- and cytopathology.
We had the intention to measure D-dimer levels daily for a period of at
least four days after the start of anticoagulation. The day of presentation
was considered to be day 0. This study was, however, restricted to the first
57 patients, because in 1999, we lost the opportunity for this clinical fol-
low-up and daily D-dimer measurements due to the decision to treat
patients with deep venous thrombosis at home.
Statistics
As D-dimer values > 8000 µg/l FEU were not diluted, no linear comparison
between the groups could be made. We have made clusters for the D-
dimer levels, with ranges 0-2000, 2001-4000, 4001-6000 and > 6000 µg/l
FEU. We used the Fisher’s exact method with two-tailed p-values for com-
parison between the clusters.
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RESULTS
In total, 218 (102 men and 116 women) consecutive outpatients with
proven deep venous thrombosis of the leg were included. Of the total of
218 patients, 49 (22%) patients had or developed cancer; 28 were already
known with cancer at the moment of thrombosis, 8 had cancer discovered
at presentation with thrombosis and 13 developed malignancy during fol-
low up (Table 1). The median follow up was 31 months (range 4-54
months). In the 8 patients who had cancer discovered at presentation, all
but one had metastatic disease. In the 13 patients who developed cancer
during follow-up, 3 had metastatic disease. The median time to the devel-
opment of cancer in the latter 13 patients was 15 months (range 3-36
months). The total prevalence of cancer in patients with deep venous
thrombosis that were not previously known with cancer was 11%
(21/190). The prevalence of cancer during follow-up was 7% (13/182).
Of the 218 patients, 102 (47%) was older than 60 years. In these 102
patients, the prevalence of cancer was 37% (38/102). This was significantly
higher than the prevalence of cancer in patients younger than 60 years
(10% (12/116); p=0.0003). The median age in patients with cancer was
higher than in patients without cancer: 67.9 years (range 30-88) versus
55.0 years (range 18-90) (p<0.001). Of the patients with thrombosis and
cancer, 78% (38/49) was older than 60 years. Of the 13 patients that
developed cancer in the follow up, 85% (11/13) was older than 60 years.
At initial D-dimer levels of 0-2000 µg/l FEU, the prevalence of cancer in the
total group was 12% (7/59), at levels 2001-4000 µg/l FEU 19% (13/69),
at levels 4001-6000 µg/l FEU 33% (9/27) and at levels > 6000 µg/l FEU
32% (20/63). Comparing the lowest with the highest cluster, this differ-
ence was statistical significant (p=0.009). The prevalence of cancer in
patients with a D-dimer < 4000 µg/l FEU was 16% (20/128) as compared
to 32% (29/90) (p=0.005) in patients with D-dimer levels > 4000 µg/l FEU
(Table 2). In patients older than 60 years, there was no difference in cancer
prevalence between patients with D-dimer levels above or under 4000 µg/l
FEU (p=0.7). In patients younger than 60 years, the prevalence of cancer
was 3% when D-dimer levels were < 4000 µg/l FEU, and 23% when D-
dimer levels were > 4000 µg/l FEU (p=0.001). 
D-dimer levels were measured at 4 consecutive days after the start of anti-
coagulation in 57 patients with proven deep venous thrombosis. All
107
D-dimers can predict cancer in DVT
patients had D-dimer levels > 500 µg/l FEU at presentation. There was a
significant decrease in D-dimer levels over time. At presentation (day 0), 25
(44%) of the 57 patients had a D-dimer concentration in the highest cluster
(> 6000 µg/l FEU); at day 4 only 8 (14%) patients had a D-dimer concen-
tration > 6000 µg/l FEU (p<0.001). Similarly, at presentation 10 (18%) of
the 57 patients had D-dimer levels in the lowest cluster (0-2000 µg/l FEU),
where at day 4 these values were 23/57 (40%) (p=0.01). However, at day
4 only 2 (4%) of the 57 patients returned to normal D-dimer levels (< 500
µg/l FEU).
Of these 57 patients, there were 12 (21%) patients with cancer; 6 were
already known with cancer, 2 had cancer discovered at presentation and in
4 patients cancer developed during follow up. In 4 of the 6 patients who
were not previously known with cancer, the D-dimer levels remained 
> 4000 µg/l FEU at day 4. Comparing the D-dimer levels in patients with
and without cancer, there was a significant difference at day 4. At day 4, 6
(50%) of the 12 patients with cancer had D-dimer levels > 4000 µg/l FEU,
where in the 45 patients without cancer only 7 (16%) had D-dimer levels 
> 4000 µg/l FEU (p=0.02). The prevalence of cancer in patients with 
D-dimer levels < 4000 µg/l FEU at day 4 was 14% (6/44), as compared to
46% (6/13) in patients with D-dimer levels > 4000 µg/l FEU (p=0.02)
(Table 2).
Of these 57 patients, 29 (51%) were over 60 years old. In these patients,
10 (34%) had cancer. A D-dimer concentration > 4000 µg/l FEU at day 4 in
these patients was associated with a cancer prevalence of 36% compared
to 33% at lower D-dimer concentrations (p=1.0). In patients younger than
60 years (n=28), 2 had cancer. These two patients both had D-dimer con-
centrations > 4000 µg/l FEU at day 4. The remaining 26 patients had no
cancer and they all had a D-dimer concentration < 4000 µg/l FEU at day 4.
These differences were statistical significant (p=0.003) (Table 2).
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Table 1. Types of malignancy in outpatients with deep venous thrombosis. 
Of the 49 patients with cancer, 28 were previously known with cancer, 
8 had cancer discovered at presentation with deep venous thrombosis 
and 13 developed cancer during follow-up.
Previously known At presentation During follow-up Total 
(n) (n) (n) (n)
Prostate 7 1 3 11
Non-Hodgkin 
lymphoma 8 - 1 9
Colorectal 3 1 4 8
Other haema-
tologic 4 - - 4
Lung 3 1 1 5
Stomach 1 - 1 2
Pancreas - 2 - 2
Breast 1 1 - 2
Ovarium - - 2 2
Other 1 2 1 4
Total 28 8 13 49  
Table 2. Prevalence of cancer in patients with deep venous thrombosis accord-
ing to D-dimer concentrations at presentation and after 4 days of 
treatment and according to age. Values are reported as percentage (n).
D-dimer concentration (µg/l FEU)   
At presentation  At day 4   
< 4000     > 4000     P value  < 4000     > 4000     P value
Total group 16 32 0.005 14 46 0.02
(20/128) (29/90) (6/44) (6/13)   
≥ 60 years 35 40 0.7 33 36 1.0
(18/52) (20/50) (6/18)  (4/11)
< 60 years 3 23 0.001 0 100 0.003
(2/76)  (9/40)  (0/26)  (2/2)   
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DISCUSSION
This study shows that in patients with deep venous thrombosis, high 
D-dimer concentrations at presentation and during the first days of treat-
ment are indicators of an increased change for overt or occult forms of 
cancer. The prevalence of cancer in patients with thrombosis reported in lit-
erature varies from 7 to 26% (6-10) and corresponds well with the cancer
prevalence of 22% in our study. Reports on the incidence of occult cancer
in idiopathic deep venous thrombosis vary from 8% to 26% (9,25,26). So
far, routine screening for cancer in every patient with deep venous throm-
bosis has not been recommended (12). There are some reports that identify
patients with thrombosis with an increased risk of having cancer. A recent
report identified the presence of bilateral deep venous thrombosis as an
independent predictive factor of cancer discovery with a hazard ratio of
6.28 compared with unilateral one (27). The risk of developing cancer in
the first year after diagnosis of thrombosis is 4 to 7 times higher in patients
with idiopathic thrombosis compared to patients with secondary thrombosis
(25,28).
We found that if the initial D-dimer concentration was > 4000 µg/l FEU,
the prevalence of cancer was significantly higher than at D-dimer levels <
4000 µg/l FEU (32% versus 16%). Also, if the D-dimer levels after 4 days
of treatment were still > 4000 µg/l FEU, the prevalence of cancer was sig-
nificantly higher than if D-dimer levels were < 4000 µg/l FEU: 46% versus
14%. This implicates that the D-dimer concentration at presentation and
after 4 days of treatment with oral anticoagulants can select patients that
are at a higher risk of having cancer. Cushman et al found no association of
baseline D-dimer with the occurrence of cancer-associated venous throm-
bosis (29). However, that study was conducted in unsymptomatic patients
with a high prevalence of a normal D-dimer concentration. They used quin-
tiles where the lowest quintile (D-dimer 2-69 µg/l) was compared with the
highest quintile (278-7429 µg/l). In our study, performed in symptomatic
patients with proven deep venous thrombosis, the D-dimer levels were all >
500 µg/l. Another difference is that the comparison of D-dimers in our
study was performed at the time of the thrombosis, and not in the periods
before.
We confirm the findings of Ranft et al, who found that 71% of patients
with deep venous thrombosis and occult cancer were over 60 years old (8).
In our study, 78% of the patients with thrombosis and cancer were older
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than 60 years and of the patients that developed cancer in the follow up,
85% was older than 60 years. Similarly, in a recent study in patients with
thrombosis, 21% of the patients over 60 years old developed cancer, com-
pared to 5% in patients younger than 60 years old (10). This shows that
the chance of having cancer in patients with deep venous thrombosis
increases with aging and this might be a stimulus to screen for occult malig-
nancy in patients older than 60 years. In our study, determination of a D-
dimer has no value in defining a subgroup of elderly with an increased
prevalence of cancer. However, in younger patients, we found a significant
difference in the prevalence of cancer when comparing D-dimer levels
above and under 4000 µg/l: 23% versus 3% for D-dimers at presentation
and 100% versus 0% for D-dimers at day 4 of treatment. Therefore, espe-
cially in younger patients with deep venous thrombosis, D-dimers might be
useful as indicators for underlying malignancy. A possible explanation for
this age-dependency may be the fact that D-dimer concentrations will be
frequently elevated in the elderly due to co-morbidity and general vessel
damage (16;30-34).
In conclusion, we found that patients with deep venous thrombosis and a
D-dimer concentration > 4000 µg/l at presentation and after 4 days of
treatment are at higher risk for developing cancer, especially when they are
younger than 60 years. Cancer-related deep venous thrombosis most fre-
quently occurs in patients older than 60 years. Our results argue for a larger
study towards cost-effectiveness of screening for a malignancy in patients
older than 60 years and in patients younger than 60 years with initially high
and persistently elevated D-dimer levels.
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CHAPTER  9
Simplification of the diagnosis of deep
venous thrombosis by using the clinical
score and D-dimer concentration
R.E.G. Schutgens1 and D.H. Biesma2
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2Department of Internal Medicine, St. Antonius Ziekenhuis Nieuwegein, 
The Netherlands
SUMMARY
Serial ultrasonography of the leg is a safe but inefficient method in diagnos-
ing patients suspected for deep venous thrombosis (DVT). With the intro-
duction of the clinical score and the D-dimer, the diagnosis of DVT is ready
for a change. It is safe to withhold anticoagulation in patients with a single
normal ultrasonography in combination with a low clinical score or a normal
D-dimer concentration. Recent studies show the safety of excluding DVT
based on the combination of a normal D-dimer and a low clinical score
alone.  This article presents an overview of recent studies about the diag-
nostic management of patients with deep venous thrombosis. 
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INTRODUCTIE
Vereenvoudiging van diagnostiek van diepveneuze trombose door gebruik
van klinische score en D-dimeer concentratie
In de diagnostiek van diepveneuze trombose (DVT) is de seriële compressie
ultrasonografie (CUS) een veilige, maar inefficiënte methode gebleken. Met
de introductie van de klinische score en de D-dimeer is de diagnostiek toe
aan een verandering. Het blijkt veilig om antistolling te onthouden aan
patiënten met een enkele normale CUS in combinatie met een lage klinis-
che score of een normale D-dimeer concentratie. Recente studies tonen aan
dat het veilig is om DVT uit te sluiten op basis van de combinatie van een
lage klinische score en een normale D-dimeer concentratie alleen. Dit artikel
geeft een overzicht van recente studies betreffende de diagnostiek van
patiënten met DVT. Diepveneuze trombose (DVT) is een relatief vaak
voorkomende aandoening met een incidentie van 1.8/1000 in de normale
populatie (1). De flebografie is lang  als gouden standaard voor de diagnos-
tiek van DVT beschouwd. Flebografie is echter invasief, duur en met  een
kleine kans op contrastallergie en iatrogene trombose. Onderzoek heeft
aangetoond dat flebografie vervangen kan worden door seriële echografie
van de beenvaten (2). Recent is dit bevestigd in twee studies, waaruit blijkt
dat de kans op het ontwikkelen van een DVT na twee normale
echografieën slechts 0.6-0.7% is (3;4). Echter, DVT komt in deze studies
slechts voor bij 17-24% van de patiënten en de tweede echografie levert
slechts bij 0.4-0.7% van de patiënten een DVT op (3;4). De seriële
echografie is dus een betrouwbare, maar inefficiënte methode in de diag-
nose van DVT. In Nederland zullen jaarlijks ongeveer 144.000 patiënten
worden verwezen in verband met de verdenking op DVT. Dit verklaart de
aandacht voor snelle en efficiënte diagnostiek.
Nieuwe niet-invasieve strategieën zijn ontwikkeld met als doel de noodzaak
tot echografie te reduceren. Hierbij wordt gebruik gemaakt van de klinische
score en het meten van de D-dimeer concentratie in plasma. 
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KLINISCHE SCORE
Wells et al ontwikkelden een score waarmee meer inzicht  werd verkregen
in de a priori kans op het bestaan van DVT (Tabel 1). Zij hebben aange-
toond dat 55-57% van de voor DVT verdachte patiënten een lage score
heeft; hiervan heeft slechts 3-5% een DVT (5;6). Een gemiddelde score
wordt gevonden bij 27-33%, met een kans van 17-33% op een DVT. 
Bij een hoge score (12-16%) is de kans op DVT 75-85%. Het voordeel van
deze klinische score is dat deze snel kan worden aangeleerd en eenvoudig
kan worden toegepast. Het nadeel is de subjectiviteit en variabiliteit:
overeenstemming tussen verschillende clinici wordt slechts bereikt in 57%
(7).
Tabel 1. Klinische score bij verdenking op diepveneuze trombose volgens 
Wells et al (5). 
gegevens uit anamnese en lichamelijk onderzoek score
maligniteit  1  
paralyse, parese of recent gips aan been 1  
recente bedrust (>3 dagen) of grote operatie (<4 weken) 1  
lokale drukpijn over diep veneus vaatbed 1  
hele been gezwollen 1  
kuit opgezet >3 cm tov andere kuit 1  
pitting oedeem beperkt tot symptomatisch been 1  
uitgezette oppervlakkige venen (niet variceus) 1  
alternatieve diagnose waarschijnlijker dan DVT -2 
hoog risico ≥ 3  
matig risico 1-2  
laag risico ≤ 0  
118
9ch
ap
te
r
D-DIMEREN
Als afbraakproduct van cross-linked fibrine neemt de D-dimeer concentratie
toe bij het optreden van fibrinolyse (Figuur 1). De toename van de concen-
tratie D-dimeren is dus een indirecte maat voor stolselvorming. De sensi-
tiviteit en negatief voorspellende waarde (NPV) van D-dimeren voor
trombose zijn hoog, maar afhankelijk van de test die gebruikt wordt. De
klassieke ELISA testen hebben een hoge sensitiviteit (97%) en NPV (93%)
(8-17). Zij zijn echter bewerkelijk en daardoor niet geschikt voor gebruik op
de spoedeisende hulp. De oudere latex-aggluttinatie testen zijn sneller,
maar hebben een aanzienlijk lagere sensitiviteit (60-80%) (8;10). Snelle
ELISA testen (zoals VIDAS®) zijn nu beschikbaar met een hoge sensitiviteit
(98-99%) en NPV (98%) (10-13;17-20). De nieuwere latex testen (zoals
Tina-quant® en STA-LIA®) zijn snel hebben nu ook een hogere sensitiviteit
(98-99%) en NPV (98%) (12;13;17;21;22). De kwalitatieve agglutinatie
test (SimpliRed®) heeft een sensitiviteit van 83% en een NPV van 93%
(8;11;12;23-29).
Een belangrijk aspect is het feit dat D-dimeren vaak verhoogd zijn bij oud-
ere patiënten en bij aandoeningen zoals infecties en maligniteiten (30-35).
Dit resulteert in een lage specificiteit voor trombose. De D-dimeer is dan
ook vooral van waarde als een exclusie test. Een normale D-dimeer sluit
trombose uit, een verhoogde D-dimeer concentratie vereist aanvullend
beeldvormend onderzoek. De specificiteit bepaalt de klinische toepas-
baarheid: een D-dimeer test met een lage specificiteit noodzaakt aanvul-
lend onderzoek (echografie) en is dus minder  kosteneffectief.
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Figuur 1. Schematische weergave van de stollingscascade.
Door weefselbeschadiging komt Tissue Factor (TF) vrij, dat bindt met geactiveerd
factor VII (VIIa) en het TF-VIIa complex vormt. Dit complex activeert factor X,
welke vervolgens protrombine omzet in trombine (IIa). Trombine zal zijn eigen pro-
ductie bevorderen via activatie van factor XI en IX. De activatie van factor X door
het TF-VIIa complex gebeurt niet alleen door directe activatie maar ook door acti-
vatie van factor IX. Het gevormde trombine zet fibrinogeen om in fibrine. Dit fibrine
wordt met behulp van factor XIII omgezet in het stabielere cross-linked fibrine. De
afbraak hiervan onder invloed van plasmine (de fibrinolyse) resulteert in het
ontstaan van fibrine afbraak producten, waarvan de D-dimeren een onderdeel zijn
(sterk vereenvoudigd model).
120
TF-VIIa Xa IIa
fibrin
XIa
IXa+VIII
fibrinogen
plasminplasminogen
cross-linked fibrin
XIIIa
fibrine degradation products
(D-dimer)
9ch
ap
te
r
NIEUWE DIAGNOSTISCHE COMBINATIES
A. Echografie en de klinische score:
In een studie van Wells et al werd bij 593 patiënten echografie gecombi-
neerd met de klinische score (6). Bij een lage klinische score (n=329) werd
één echografie verricht: DVT werd gevonden bij 9 patiënten. Gedurende de
follow-up van 3 maanden werd bij slechts 1 (0.3%) van de 320 een DVT
geconstateerd. Patiënten met een gemiddelde score (n=193) ondergingen
twee echografieën; de eerste toonde 27 maal een DVT aan, de tweede 3.
In de follow-up ontwikkelden 2 (1.2%) van de 163 patiënten een DVT.
Patiënten met een hoge score (n=71) ondergingen één echografie; 49 had-
den een DVT. Een normale echografie werd gevolgd door een flebografie
die bij 4 patiënten een DVT aantoonde. In de follow-up kreeg niemand van
de overigen in deze groep een DVT. Deze studie toont aan dat het veilig is
om antistolling te onthouden aan patiënten met een lage klinische score en
één normale echografie.
Tick et al (36) publiceerden in een serie van 811 patiënten onder andere de
resultaten van de follow-up van 280 (35%) patiënten met een lage klinis-
che score. Eénmalig echografisch onderzoek liet een DVT zien bij 30 van de
280 patiënten. Bij 5 (2.0%) van de 250 personen met een normale
echografie werd gedurende de follow-up van 3 maanden een DVT gecon-
stateerd. Dit  percentage ligt hoger dan bij de studie van Wells et al (6).
Wellicht wordt dit verklaard door de hogere prevalentie van DVT in deze
studie: 41% versus 16%. Een mogelijke verklaring hiervoor is dat er een
selectie van patiënten heeft kunnen plaatsvinden in de studie van Tick et al
door tussenkomst van de huisarts. 
B. Echografie en D-dimeren:
In een studie van Bernardi et al (37) ondergingen 946 patiënten een
echografie;  260 patiënten hadden een DVT. Van de overige 686 patiënten
hadden 598 een normale D-dimeer concentratie; bij hen werd afgezien van
een tweede echografie. De incidentie van DVT na een normale D-dimeer
en normale echografie was 0.2%. 
In een vergelijkbare studie van Kraaijenhagen et al (38) werden 1739
patiënten onderzocht. Middels een echografie werd bij 391 patiënten een
DVT aangetoond.  Van de overige 1348 patiënten hadden 828 een normale
D-dimeer concentratie. Hiervan ontwikkelde slechts 0.6 % een trombose in
de follow-up.
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Deze twee studies laten zien dat het veilig is om DVT uit te sluiten bij een
normale D-dimeer concentratie en een enkele normale echografie.
C. Combinatie van de klinische score en D-dimeren:
De vraag of een DVT kan worden uitgesloten op basis van een niet-hoge
klinische score en een normale D-dimeer concentratie werd onderzocht in
een recente Nederlandse studie (21). Bij  812 patiënten met de verdenking
op een DVT werden een klinische score volgens Wells en een D-dimeer
concentratie bepaald. De klinische score werd onderverdeeld in niet-hoog
(< 3) en hoog (≥ 3). Het diagnostische traject is weergegeven in Figuur 2.
De totale prevalentie van trombose in deze studie was 39% (309 DVT bij
presentatie en 8 veneuze tromboembolie tijdens follow-up). De resultaten
zijn weergegeven in Tabel 2. Van de 176 patiënten met een normale D-
dimeer en een niet-hoge score kreeg 1 (0.6%) patiënt een kuitvenetrom-
bose na 1 week (NPV van 99.4%). Bij 3 van de 39 patiënten met een
normale D-dimeer en een hoge score was sprake van een DVT bij presen-
tatie en één patiënt ontwikkelde een longembolie na 71 dagen (NPV
97.2% in deze groep). De overige 597 patiënten ondergingen herhaald
echografisch onderzoek: de eerste echografie was afwijkend bij 291 patiën-
ten en de tweede bij 15 patiënten. Bij 6 (2.1%) van de 291 met twee nor-
male echografieën werd trombose tijdens de follow-up gevonden (NPV
97.9%). In deze studie werd het aantal echografieën gereduceerd met
29%. Deze studie laat zien dat het veilig is om DVT uit te sluiten op basis
van een normale D-dimeer concentratie en een niet-hoge klinische score.
Een soortgelijke conclusie werd getrokken in 3 vergelijkbare studies (Tabel
3). In de studie van Janes et al (24) werd een gemodificeerde Well’s score
gebruikt, en in de studies van Kearon et al (25) en Anderson et al (39) de
originele Well’s score. Voor de exclusie van DVT werd door Schutgens et al
een lage of gemiddelde score gebruikt, terwijl in de overige studies alleen
een lage score werd gebruikt. Het verschil tussen de eerstgenoemde studie
en de laatste 3 studies is dat in de eerste studie een D-dimeer test is
gebruikt met een beduidend hogere sensitiviteit en NPV (Tina-quant® ver-
sus SimpliRed®). Het gebruik van een hoog sensitieve D-dimeer test draagt
er toe bij dat ook bij patiënten met een gemiddelde klinische score en een
normale D-dimeer een DVT kan worden uitgesloten. Bij gebruik van een
minder sensitieve test wordt meer nadruk gelegd op de klinische score:
alleen in geval van een lage score en een normale D-dimeer kan een DVT
worden uitgesloten. 
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Figuur 2. Diagnostisch traject voor patiënten verdacht voor DVT, zoals gebruikt in
de studie van Schutgens et al (21).
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Tabel 2. Prevalentie van veneuze tromboembolie volgens D-dimeer concentratie 
en klinische score (21).
Groep N VTE in follow-up Totaal VTE  
Normale D-dimeer 176 (22%) 1 (0.6%;0.02-3.1) 1 (0.6%;0.02-3.1)
en niet-hoge score   
Normale D-dimeer 39 (5%) 1 (2.8%;0.07-14.5) 4 (10.3%;2.9-24.2)
en hoge score 
Normale D-dimeer  215 (26%) 2 (0.9%;0.1-3.4%) 5 (2.3%;0.8-5.3%)
Abnormale D-dimeer 597 (74%) 6 (2.1%;0.8-4.4) 312 (52.3%;48.3-56.3)
Totaal 812 (100%) 8 (1.6%;0.7-3.1) 317 (39.0%;35.7-42.4)  
Waarden zijn gerapporteerd in aantallen (percentage;95% betrouwbaarheids 
intervallen). VTE betekent veneuze tromboembolie (diepveneuze trombose en 
longembolie).
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Tabel 3. Overzicht van management studies naar de diagnostiek van diep-
veneuze trombose met behulp van de klinische score en D-dimeren.
Studie N Prevalentie  Exclusie van DVT NPV
VTE op basis van D-dimeer 
en klinische score   
Schutgens et al (21) 812 39% 176 (22%) 99.4%  
Janes et al (24) 404 24% 98 (24%) 99.0%  
Kearon et al (25) 445 14% 177 (40%) 99.4%  
Anderson et al (39) 1075 18% 316 (29%) 98.4%
VTE = veneuze tromboembolie, DVT = diepveneuze trombose, NPV = negatief
voorspellende waarde van de combinatie van de klinische score en D-dimeren.
D. D-dimeren:
Perrier et al suggereerden veneuze trombo-embolieën uit te sluiten op basis
van alleen een normale D-dimeer concentratie (20). Bij 23% van de 918
patiënten bij wie de diagnose DVT of longembolie (LE) werd vermoed werd
een trombose gevonden. In dit onderzoek hadden 288 (31%) patiënten
een normale D-dimeer en werd in principe geen aanvullend onderzoek ver-
richt. Als veiligheidsmaatregel werd bij deze patiënten echter alsnog een
echografie verricht. Bij 2 (0.7%) van de 288 patiënten werd hierdoor een
DVT ontdekt. In de follow-up was er niemand die een DVT ontwikkelde. In
deze studie was bij 474 patiënten alleen verdenking op een DVT; 127 van
deze 474 patiënten hadden een normale D-dimeer. Geen van deze patiën-
ten ontwikkelde een DVT in de follow-up. Deze studie suggereert dat het
veilig is om trombose uit te sluiten op basis van een normale D-dimeer con-
centratie alleen, hoewel dit niet in andere, prospectieve studies is bevestigd.
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Conclusies en aanbevelingen
In de huidige consensusstrategie voor DVT wordt uitgegaan van herhaalde
echografieën. Deze strategie zal echter moeten worden aangepast op basis
van de resultaten van bovengenoemde studies. 
Het is veilig om de tweede echografie achterwege te laten in geval van een
normale eerste echografie en een lage klinische score of normale D-dimeer
bij presentatie. Recente studies tonen aan dat het ook veilig is om DVT uit
sluiten op basis van een lage  klinische score in combinatie met een normale
D-dimeer zonder aanvullende beeldvormende diagnostiek en, waarschijn-
lijk, ook op basis van een gemiddelde klinische score met een normale,
hoog sensitieve, D-dimeer test. Lokale factoren, zoals type D-dimeer test,
ervaring met de klinische score en prevalentie van DVT zullen de keuze
voor een diagnostische strategie bepalen.
Routinematig gebruik van de D-dimeer test bij alle patiënten wordt niet
aangeraden. De sensitiviteit van de D-dimeer test daalt aanzienlijk (van
99% naar 75%) bij patiënten die orale antistolling gebruiken (34). Bij deze
patiënten dient het gebruik van de D-dimeer te worden vermeden. In
patiënten met kanker lijkt de NPV gelijk aan patiënten zonder kanker
(34;40), hoewel een andere studie het tegendeel bewijst (41). De speci-
ficiteit in deze patiënten lijkt verlaagd (34;41), hoewel dit niet in elke studie
wordt gevonden (40). Nader onderzoek naar de waarde van D-dimeren in
deze patiënten is vereist. Daarnaast zijn alle bovenstaande management
studies gedaan bij ambulante patiënten. Bij patiënten die zijn opgenomen in
een ziekenhuis zal de D-dimeer concentratie vaak verhoogd zijn door co-
morbiditeit. Dat leidt tot een sterke afname van de specificiteit van de D-
dimeer test. Routinematig gebruik van deze test is niet aan te raden bij deze
patiëntencategorie. Een lage specificiteit is ook gevonden bij patiënten op
hoge leeftijd (30-35). Ook bij deze populaties levert een D-dimeer bepaling
weinig winst in het diagnostisch traject op. Overigens is de sensitiviteit in
deze groep patiënten niet verminderd (34).
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SUMMARY
Measurement of D-dimer concentrations is supposed to be a promising tool
in the diagnostic workup of venous thromboembolism (VTE). The subject of
this thesis is to refine the role of the D-dimer in the exclusion of venous
thrombosis.
The sample material for measurements of D-dimer concentration is citrate
plasma. This is inconvenient for the clinical chemistry workflow, as an extra
sample for D-dimer measurements is needed and citrate samples are cen-
trifuged separately from heparin plasma. Furthermore, little is known about
the effect of (pre)analytic processes on the outcome of D-dimer measure-
ments. In chapter 2, we compared D-dimer measurements in citrate and
heparin plasma from 190 patients. We found a high correlation between
the two samples (r=1.0, slope=1.196, Kendall tau=0.95). The D-dimer con-
centrations in heparin were 19% higher than in citrate plasma, which was
totally explained by the extra dilutional effect of citrate plasma. We found
no effect of transport in 25 samples by dispatching them by pneumatic mail
and by placing them on an oscillating roller. Sample stability was measured
in samples that were left standing at room temperature for 16 and 24
hours, in samples that were snap-frozen once and in samples that were
frozen at –70ºC. No differences in D-dimer concentrations were found
between these samples. Finally, we performed D-dimer measurements on 4
different analyzers: a high correlation between the samples was found. 
This study shows that it is valid to measure D-dimer concentrations using
heparin plasma on routine chemical analyzers. A correction factor of 0.84
has to be applied to avoid the need for a change in reference and cut-off
values, as all reports in literature are based on the standard citrate solution.
This finding implicates a significant improvement in reporting the D-dimer
results by a reduction of the turn-around time. Furthermore, we found D-
dimer concentrations to remain stable under various (pre)analytic condi-
tions, making comparison of different studies more feasible.
It is of clinical importance to be informed about the time of increase and
decrease in D-dimer concentration in venous thromboembolism. This allows
to establish the optimal time of D-dimer testing and to define the time-peri-
od before and after which a D-dimer test may have reduced accuracy. In
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addition, it is of interest to be informed about the correlation between the
size of the thrombus and the extent of D-dimer concentration, as large
thrombi may lead to a more aggressive therapeutic approach and to a more
careful monitoring. These questions have been addressed in chapter 3,
where we studied the course of D-dimer concentrations in patients under-
going embolisation of pulmonary arteries because of pulmonary arteriove-
nous malformations (PAVM) and calculated the correlation between
D-dimer concentrations and the estimated size of the thrombus. In 13
patients with hereditary hemorrhagic teleangiectasia (HHT) or Rendu-
Osler-Weber disease who underwent embolisation because of PAVM caus-
ing hypoxemia and increased right-to-left shunts, we measured D-dimer
concentrations at 2, 4 and 8 hours after the embolisation. The control
group consisted of 14 patients who underwent diagnostic heart catheterisa-
tion without any intervention. At t=2 hours, D-dimer concentrations in the
patient group were significantly higher as compared to baseline (p=0.001),
and remained significantly higher at t=4 and t=8 hours. The control group
showed no significant increase in D-dimer concentration as compared to
baseline. The increase in D-dimer concentration in the patient group dif-
fered significantly from the control group (p=0.047). 
We found a correlation between D-dimer concentration and the calculated
volume of the parts of the pulmonary arteries that were embolised, but not
between D-dimer concentration and the decrease of the right to left shunt
or the increase in pO2.
This study shows that D-dimer concentrations increase almost immediately
after formation of a clot and that they remain elevated for at least 8 hours
after onset. Furthermore, the height of the D-dimer concentration might
help to predict the extent of the thrombus.
Although high sensitivity and negative predictive value of D-dimers in
venous thrombosis have been reported in outpatients, its clinical usefulness
will also be determined by the specificity of the test. In chapter 4, we tried
to define clinical and laboratory variables that might restrict the use of the
D-dimer in terms of reduced sensitivity, negative predictive value or speci-
ficity. In 704 outpatients suspected of having DVT, the performance of a
latex agglutination D-dimer test (Minutex®) was calculated in patients
using anticoagulants (n=61), patients with previous thrombosis (n=127),
and patients with malignancy (n=47), including 39 patients with more than
one of these characteristics. The 508 remaining patients were considered to
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be the reference group. A total of 254 patients (36%) had evidence of
deep venous thrombosis. The D-dimer test had a sensitivity of 99% and a
negative predictive value of 98% in the reference group. The sensitivity of
the D-dimer test in patients using oral anticoagulants was 75% (p=0.01
compared with the reference group) and the negative predictive value was
93%. Anticoagulated patients were more likely to have a negative D-dimer
test as compared to the reference group (46% vs. 20%, p<0.001). Test
sensitivity and negative predictive value were respectively 96% and 94% in
patients with previous thrombosis, and 100% in patients with cancer. In
cancer patients, 91% had an abnormal D-dimer test. The prevalence of a
positive D-dimer test increased with age. In patients aged ≥ 70 years, 79%
had a positive D-dimer test, compared with 61% of younger patients 
(p=0.0001).
This study shows that the overall sensitivity and negative predictive value of
this rapid latex D-dimer assay for the exclusion of deep venous thrombosis
are high. The D-dimer test has a good performance in patients with previ-
ous venous thromboembolism, but we do not recommend its use in
patients using oral anticoagulants because of the reduced sensitivity of the
test. The D-dimer tests in patients with cancer and in patients over 70 years
old are usually positive and may not be worthwhile in terms of low speci-
ficity.
Serial ultrasonography is reliable for the diagnosis of deep venous thrombo-
sis in symptomatic patients, but the low prevalence of thrombosis in this
group renders this approach costly and inconvenient to patients. 
In chapter 5, we studied the clinical validity of the combination of a pretest
clinical probability score and a D-dimer test in the initial evaluation of
patients suspected of deep venous thrombosis. In 812 consecutive outpa-
tients, a clinical score and a D-dimer test (Tina-quant®) were performed. A
total of 176 patients had a normal D-dimer concentration (< 500 FEU µg/L)
and a non-high probability score (< 3) and had no further testing. Only 1
(0.6%) of these patients developed thrombosis in the 3 months follow-up
period. A normal D-dimer concentration and a high probability score were
found in 39 patients; in these patients, a single ultrasonography was per-
formed. Three of these patients (7.7%) had thrombosis at presentation,
and one (2.8%) developed pulmonary embolism during follow-up. Serial
ultrasonography was performed in patients with an abnormal D-dimer con-
centration. In 306 of 597 patients (51.3%) with an abnormal D-dimer con-
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centration, thrombosis was detected by serial ultrasonography. Six patients
(2.1%) developed thrombosis during follow-up. No deaths due to throm-
boembolism occurred during follow-up. Deep venous thrombosis or pul-
monary embolism was diagnosed in 317 (39%) patients during the entire
study period.
This study shows the safety of withholding anticoagulation in patients sus-
pected of having deep venous thrombosis with the combination of a nor-
mal D-dimer concentration and a non-high clinical score. This strategy
reduces the need for ultrasonography by approximately 30%.
For measurement of D-dimer concentrations, several assays are available.
Where earlier D-dimer assays were time consuming or showed less sensitiv-
ity for thrombosis, new D-dimer assays have now been introduced. They
claim to be fast and highly sensitive, but need clinical validation. 
In chapter 6, we evaluated the clinical usefulness of four relatively new 
D-dimer assays and a classical ELISA in 537 outpatients suspected for deep
venous thrombosis. Patients were participants in a large prospective man-
agement study using a clinical probability score and a D-dimer measure-
ment (Tina-quant®). Additional samples were taken for D-dimer
measurement using the Asserachrom  ELISA®, the VIDAS New®, the STA-
LIA® and the Miniquant® assay. Performances of each test were calculated
using clinical data during a 3-months follow-up. Thrombosis was detected
in 224 patients (42%). The area under the ROC curve was significantly
higher for the Tina-quant® as compared to the other assays. Using standard
cut-off values, sensitivity, negative predictive value and specificity of the
Asserachrom® were 97, 94 and 33% respectively. For the VIDAS New®,
values were 100, 96 and 8% respectively. The Tina-quant® showed values
of 99, 98 and 41% respectively and the STA-LIA® 98, 95 and 32%. Values
for the Miniquant® were 95, 94 and 52%. Lowering the cut-off values
resulted in an improvement of sensitivity and negative predictive value, but
in a decrease of specificity, rendering the tests less useful in clinical practice. 
This study shows that the D-dimer assays, used in this study, all show a
high sensitivity and negative predictive value, but none of the assays
reached an NPV of > 98% at standard cut-off values. For exclusion of DVT,
we therefore recommend combining the D-dimer assay with other non-
invasive tests in order to reach failure rates less than 1.0%. The use of 
D-dimer assays with a very low specificity might not be worthwhile from an
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economical point of view, as a positive test will necessitate additional test-
ing in the majority of the patients.
Intravenous administration of unfractionated heparin (UFH) has proven its
efficacy in the early treatment of venous thromboembolism. The use of
UFH, however, has several inconveniences, such as the need for hospitalisa-
tion and frequent monitoring of activated partial thromboplastin times.
Treatment of deep venous thrombosis and pulmonary embolism with low-
molecular-weight heparin (LMWH) is considered to be equally safe as UFH
when looking at clinical outcome, but little is known about differences
between UFH and LMWH on coagulation activity during treatment for pul-
monary embolism. In chapter 7, we compare UFH and LMWH in the early
treatment of pulmonary embolism in terms of control of coagulation mark-
ers and perfusion abnormalities in a randomised, non-blinded study.
Therefore, 37 patients with acute pulmonary embolism were randomised to
receive intravenous UFH or subcutaneous dalteparin; both groups also
receive acenocoumarol. Blood samples were obtained before treatment and
daily for 4 consecutive days. Thrombin generation was assessed by measur-
ing fragments 1+2 (F1+2), thrombin-antithrombin (TAT)-complexes and
fibrin monomers. F1+2 and TAT-complexes rapidly normalised without dif-
ferences between the groups. Fibrin monomer levels did not decrease, and
showed an increase in the UFH group from day 3. Fibrinolysis was analysed
by measuring D-dimer concentrations and clot lysis times. D-dimer levels
decreased over time, without differences between the groups. Clot lysis
times were shorter in the UFH group. In vitro inactivation of thrombin acti-
vatable fibrinolysis inhibitor (TAFI) by carboxypeptidase-inhibitor eliminated
any further effect of heparin on clot lysis times, confirming that the effect
of heparin on the clot lysis time is mainly through TAFI. Ventilation-perfu-
sion scintigraphies were performed from which the percentage-of-vascular-
obstruction scores (PVOs) were calculated at day 0 (PVOsD0) and day 5
(PVOsD5). The PVOsD0 and PVOsD5 were not different, but the decrease
of the PVOs over time was higher in the LMWH group.
This study shows that LMWH (dalteparin) is at least equally effective as
UFH in reducing coagulation activity and in prohibiting further increases in
perfusion abnormalities in the early treatment of pulmonary embolism. Our
findings support the use of LMWH as initial treatment of pulmonary
embolism.
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Venous thromboembolism can be related to malignancy, but routine
screening for cancer in every patient with deep venous thrombosis is a mat-
ter of debate. In chapter 8, we investigated if the initial height of the D-
dimer concentration or the D-dimer concentrations during treatment for
DVT can be used as a predictor for (occult) malignancy. We studied 218
consecutive outpatients with proven DVT, in whom a D-dimer test was per-
formed. Patients were followed for a median of 31 months and the occur-
rence of malignancy was documented. In total, 49 (22%) patients had or
developed cancer; 28 were already known with cancer at the moment of
thrombosis, 8 had cancer discovered at presentation with thrombosis and
13 developed malignancy during follow up. The prevalence of cancer in
patients with an initial D-dimer < 4000 µg/l FEU was 16% (20/128) as
compared to 32% (29/90) (p=0.02) in patients with D-dimer levels > 4000
µg/l FEU. The prevalence of cancer in patients with D-dimer levels < 4000
µg/l FEU at day 4 was 14% (6/44), as compared to 46% (6/13) in patients
with D-dimer levels > 4000 µg/l FEU (p=0.02). Furthermore, the prevalence
of cancer in patients older than 60 years was higher compared to younger
patients (37% vs. 10%; p=0.0003). Of the patients with thrombosis and
cancer, 78% (38/49) was older than 60 years. Of the 13 patients that
developed cancer in the follow up, 85% (11/13) was older than 60 years.
In patients older than 60 years, there was no difference in cancer preva-
lence between patients with D-dimer levels above or under 4000 µg/l FEU
(p=0.7). In patients younger than 60 years, the prevalence of cancer was
3% when initial D-dimer levels were < 4000 µg/l FEU, and 23% when D-
dimer levels were > 4000 µg/l FEU (p=0.001). After 4 days of treatment,
cancer prevalences were 0% and 100% in younger patients with D-dimer
levels < and > 4000 µg/l respectively (p=0.003).
This study shows that high D-dimer concentrations at presentation and
during the first days of treatment are indicators of an increased change for
overt or occult forms of cancer, especially in patients younger than 60
years. Cancer-related deep venous thrombosis is more frequent in patients
older than 60 years. The D-dimer concentration in patients older than 60
years does not contribute to discriminate between patients with and with-
out cancer.
An overview of recent published articles on the diagnostic management of
deep venous thrombosis is given in Chapter 9.
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The diagnosis of deep venous thrombosis (DVT) is subject to important
changes with the introduction of D-dimers and the clinical score. It has now
been established that it is safe to withhold anticoagulant treatment in
patients suspected for having DVT with a low/moderate clinical score and a
normal D-dimer concentration. This thesis has given more insight in the use
of D-dimers in the diagnosis and management of venous thrombosis.
However, certain questions yet remain unanswered.
Do we have to use D-dimers on a routine base in the diagnostic manage-
ment of every patient suspected for having DVT?
In this thesis, we showed the decrease in sensitivity of the D-dimer test in
patients with oral anticoagulation (chapter 4). Decreases in sensitivity and
specificity of the D-dimer test have also been reported in hospitalized
patients (1;2). Larger prospective studies are needed in hospitalized patients
and in patients on anticoagulants before firm conclusions can be made.
Reports about the sensitivity and negative predictive value (NPV) of the D-
dimer tests in patients with cancer vary. Some authors suggest that the NPV
of the D-dimer test in patients with cancer is comparable with that of
patients without cancer (3;4), whereas others report the contrary (5). The
specificity of the D-dimer test in the patients with a malignancy is found to
be lower in two studies (3;5), which was, however, not confirmed in anoth-
er study (4). More studies about the reliability of the D-dimer test to
exclude DVT in cancer patients are warranted.
What is the optimal diagnostic strategy in DVT?
Several diagnostic strategies have been suggested in literature, varying
from the use of D-dimers alone to several combinations of venography,
ultrasonography, pretest clinical score and D-dimer tests. In this thesis, we
presented the safety of diagnosing DVT using combinations of the clinical
score, the D-dimer and ultrasonography (chapter 5). In our model, how-
ever, the second ultrasound showed DVT in only 15 (4.9%) out of 306
patients. We suggest a new diagnostic strategy for patients suspected for
DVT, based on our studies and some recently published studies from other
groups (Figure 1). The challenge for further research will be the reduction
of the need for the second ultrasound in this strategy. 
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How to improve the clinical use of the D-dimer in the elderly?
Several reports (this thesis included) have documented the increase in D-
dimer concentrations in the elderly (6-11). Age-adjusted cut-off values may
improve the specificity of the D-dimer test. Another possibility is to restrict
the use of the D-dimer test in the elderly to patients without co-morbidity
in an attempt to improve the specificity of the D-dimer test.
Are D-dimers the only laboratory markers for excluding thrombosis?
Although most studies have focused on the D-dimer tests in the exclusion
of thrombosis, it is of interest to know if there are other coagulation or fibri-
nolytic markers that can be used for this purpose. Previous reports on fibrin
monomers in the exclusion of DVT were discouraging (12) to promising
(13;14). A recent report discussed the potential role of fibrin monomer-fib-
rinogen complexes in the diagnosis of thrombosis (15). Whether fibrin
monomers could be used in combination with D-dimers to further reduce
the need for ultrasound remains to be investigated. Other markers for
thrombin generation, like thrombin-antithrombin complexes and fragments
1+2, were inferior to the D-dimer concentration (16;17). Larger prospective
studies are needed to determine the possible role of these coagulation
markers as tools in the exclusion of thrombosis.
Can D-dimers be used to predict recurrent thrombosis or occult diseases?
Recent reports have showed that persistently elevated D-dimer concentra-
tions can predict recurrence of thrombosis (18;19). We suggest that high D-
dimer levels are associated with an increased the risk for cancer. Repeated
measurement of D-dimers concentrations during the treatment of patients
with DVT might be used to select a subgroup of patients in whom an
extended search for occult cancer can be justified.
The D-dimer test forms an intriguing contribution to the diagnostic man-
agement of patients suspected for having DVT. We support the incorpora-
tion of the D-dimer test in the diagnostic standards of care for these
patients. The place of the D-dimer test in several subgroups of patients
needs further attention.
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Figure 1. Diagnostic flowchart for patients suspected for having deep venous 
thrombosis (DVT).
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SAMENVATTING IN HET NEDERLANDS
Diepveneuze trombose (DVT) is een aandoening waarbij er een stolsel
(trombose) ontstaat in één van de bloedvaten van het been of in het kleine
bekken (of in zeldzame gevallen op andere plaatsen). Wanneer er een deel
van dit stolsel loslaat, kan dit via de bloedstroom meegevoerd worden,
waarna het stolsel blijft steken in de kleine bloedvaten van de long. Dit ver-
schijnsel heet een longembolie.
Het stellen van de diagnose van DVT wordt veelal gedaan door middel van
een echografisch onderzoek. Echter, dit onderzoek kan kleine stolsels in de
kuit missen. Daarom wordt een tweede echografie verricht na een week,
om een eventueel gemiste trombose alsnog te detecteren. Hoewel dit een
veilige methode is gebleken, is het erg inefficiënt: slechts een kwart van de
patiënten heeft daadwerkelijk een trombose en het rendement van de
tweede echografie is erg laag. 
Het meten van D-dimeer concentraties is een veelbelovend hulpmiddel in
de diagnostiek van DVT. D-dimeren zijn afbraakproducten van fibrine (een
stolsel bestaat voornamelijk uit fibrine), en aldus een indirecte maat voor
het ontstaan van trombose. Bij iedereen is er een bepaalde hoeveelheid D-
dimeer aanwezig, maar in geval van een stolsel zal de concentratie stijgen.
Het onderwerp van dit proefschrift is de rol van D-dimeren bij de diagnos-
tiek van DVT te verfijnen.
Het materiaal waarin D-dimeren in het laboratorium worden gemeten is 
citraat plasma, in tegenstelling tot heparine plasma waarin de routine
bepalingen worden gemeten. Dit is onhandig voor de klinisch chemische
analyse, omdat hiervoor een extra buis dient te worden afgenomen en
omdat citraat plasma een andere bewerking dan heparine plasma onder-
gaat hetgeen vooral veroorzaakt wordt door een andere (langere) wijze van
centrifu-geren. Verder is weinig bekend over de effecten van de wijze
waarop het materiaal behandeld wordt op de D-dimeer concentratie. In
hoofdstuk 2 vergeleken wij D-dimeer bepalingen in citraat en heparine
plasma van 190 patiënten. We vonden een hoge correlatie tussen de twee
bepalingen. De D-dimeer concentraties waren 19% hoger in heparine plas-
ma dan in citraat plasma, wat volledig verklaard kan worden door de extra
verdunning die plaatsvindt in citraat plasma. Er was geen effect van trans-
port in 25 buisjes die door middel van buizenpost werden verstuurd of op
een bewegende roller werden geplaatst. De stabiliteit van de bepaling werd
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gemeten in buisjes die op kamertemperatuur werden bewaard gedurende
16 en 24 uur, in buisjes die éénmalig kortdurend werden ingevroren en in
buisjes die 2 jaar lang bewaard werden bij een temperatuur van -70oC. Er
werd tussen deze bepalingen geen verschil gevonden in D-dimeer concen-
tratie. Tenslotte werden vier verschillende technieken gebruikt voor de
bepaling; er werd geen verschil gevonden in de gebruikte apparatuur.
Deze studie toont dat D-dimeren bepaald kunnen worden in heparine plas-
ma op routine chemische machines. Een correctiefactor van 0.84 dient te
worden gebruikt om een verandering in referentiewaarden en grens-
waardes te vermijden, aangezien alle literatuur gebaseerd is op standaard
citraat plasma. Dit gegeven betekent een duidelijke verkorting van de
reportagetijd van de D-dimeer uitslagen hetgeen leidt tot een kortere
wachttijd op de eerste hulp. Tevens toonden wij aan dat de D-dimeer con-
centratie stabiel blijft onder verschillende omstandigheden. Aangezien
ingevroren materiaal representatieve gegevens blijft geven, is het verant-
woord om met dit materiaal verder onderzoek te verrichten.
Het is van belang om geïnformeerd te zijn over het tijdstip van ontstaan en
verdwijnen van de D-dimeren in geval van veneuze trombose. Dit helpt het
optimale tijdstip voor een D-dimeer bepaling in te schatten en de periode te
bepalen waarvoor en waarna een D-dimeer test minder accuraat kan zijn.
Verder is het van belang te weten of er een samenhang is tussen de hoogte
van de D-dimeren en de grootte van het stolsel, aangezien grotere stolsels
mogelijk aanleiding kunnen zijn voor een intensievere behandeling. Deze
vragen stellen wij in hoofdstuk 3, waar wij het beloop van de D-dimeer
concentraties hebben bestudeerd bij patiënten die een behandeling
ondergingen van afwijkende bloedvaten in de long (pulmonale arteri-
oveneuze malformaties [PAVM]) ten gevolge van de ziekte van Rendu-
Osler-Weber. De behandeling bestaat uit het afsluiten van de afwijkende
bloedvaten door het creëren van een stolsel in het bloedvat (=embolisatie).
Tevens hebben wij de relatie tussen de D-dimeer concentraties en de
geschatte grootte van het stolsel berekend. Bij 13 patiënten met de ziekte
van Rendu-Osler-Weber die een embolisatie ondergingen van PAVM, wer-
den D-dimeer concentraties gemeten vóór, 2, 4 en 8 uur na de embolisatie.
De controle groep bestond uit 14 patiënten die een hartkatheterisatie
ondergingen zonder verdere ingreep. Twee uur na aanvang van de ingreep
(t=2 uur), waren de D-dimeer concentraties in de patiënten groep reeds
hoger dan de uitgangswaarden (p=0.001) en deze waarden bleven ver-
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hoogd op t=4 en 8 uur. De controle groep toonde geen toename van de D-
dimeer concentratie. De stijging van de D-dimeer concentraties in de
patiënten groep was hoger dan in de controle groep. Wij vonden eveneens
een relatie tussen de hoogte van de D-dimeer concentratie en het berek-
ende volume van de gedeeltes van de arteriën die werden geëmboliseerd,
maar geen relatie tussen de D-dimeer concentratie en de afname in de
rechts-links shunt of de stijging van het zuurstofgehalte.
Deze studie toont aan dat de D-dimeer concentraties vrijwel direct stijgen
na het ontstaan van een (kunstmatig) stolsel en dat ze minstens 8 uur na
ontstaan verhoogd blijven. De hoogte van de D-dimeer concentratie zou
een inschatting kunnen geven van de grootte van het stolsel.
In de literatuur is beschreven dat de gevoeligheid (sensitiviteit) en de
negatief voorspellende waarde van de D-dimeertest voor veneuze trom-
bose hoog is, maar de klinische toepasbaarheid wordt mede bepaald door
de specificiteit. In hoofdstuk 4 hebben wij geprobeerd om klinische variabe-
len te definiëren welke de toepasbaarheid van de D-dimeer zouden kunnen
doen verminderen en zouden leiden tot een verminderde sensitiviteit of
specificiteit. Bij 704 patiënten, bij wie een DVT werd vermoed, werd de
waarde van een D-dimeertest (Minutex®) berekend. Deze groep patiënten
werd onderverdeeld in een groep met bloedverdunnende middelen (n=61),
een groep met een eerder doorgemaakte trombose (n=127) en een groep
patiënten met kanker (n=47). De referentiegroep bestond uit patiënten
zonder bloedverdunners, eerdere trombose of kanker. In totaal werd bij 254
patiënten (36%) een trombose aangetoond. De D-dimeertest had een sen-
sitiviteit en negatief voorspellende waarde van respectievelijk 99% en 98%
in de referentiegroep. De sensitiviteit bij patiënten met bloedverdunners
was met 75% aanzienlijk lager dan de referentiegroep. Tevens hadden de
patiënten die bloedverdunners gebruikten vaker een normale D-dimeertest
in vergelijking met de referentiegroep (46% versus 20%). Bij patiënten met
eerdere trombose was de sensitiviteit 96% en de negatief voorspellende
waarde 94%; bij patiënten met kanker waren deze beide waarden 100%.
Bij patiënten met een vorm van kanker was  in 91% sprake van een ver-
hoogde D-dimeer concentratie. De kans op een verhoogde D-dimeeruitslag
stijgt met de leeftijd: 79% van de patiënten ouder dan 70 jaar had een ver-
hoogde D-dimeer waarde in vergelijking met 61% in de jongere patiënten.
Deze studie toont aan dat de gebruikte D-dimeertest een hoge sensitiviteit
en negatief voorspellende waarde voor trombose heeft. De D-dimeertest is
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van waarde bij patiënten met eerdere trombose, maar is waarschijnlijk min-
der betrouwbaar bij patiënten met bloedverdunners. De D-dimeertest is
vaak verhoogd bij patiënten met kanker en bij oudere patiënten.
Het herhaald verrichten van een echografie van de beenvaten is een veilige,
maar inefficiënte methode gebleken bij de diagnostiek van DVT. 
In hoofdstuk 5 bestuderen wij de waarde van de combinatie van een klinis-
che score en de D-dimeer bij de beoordeling van patiënten met een ver-
denking op DVT. Bij 812 patiënten (uit 4 verschillende ziekenhuizen) werd
een klinische score en een D-dimeer (Tina-quant®) meting verricht. Er
waren 176 patiënten met een niet-hoge score en een normale D-dimeer
concentratie; bij deze patiënten werd geen aanvullend onderzoek verricht.
Slechts 1 (0.6%) van deze patiënten kreeg een trombose in de daarop vol-
gende follow-up periode van 3 maanden. Negenendertig patiënten hadden
een normale D-dimeertest en een hoge klinische verdenking op DVT; bij
deze groep werd eenmalig een echografie van de beenvaten verricht. Drie
(7.7%) van deze patiënten had een DVT bij presentatie, en 1 (2.8%) kreeg
een longembolie in de follow-up periode. Er werd tweemaal een echografie
verricht bij patiënten met een verhoogde D-dimeer concentratie. Bij 306
van deze 597 patiënten werd hierbij een DVT geconstateerd. Zes (2.1%)
patiënten ontwikkelden een trombose gedurende de follow-up van 3
maanden. Gedurende de gehele studieperiode werd bij 317 patiënten
(39%) een trombose gevonden.
Deze studie toont aan dat het veilig is een DVT uit te sluiten op basis van
de combinatie van een niet-hoge klinische score en een normale D-dimeer
concentratie. Deze methode resulteert in een afname van bijna 30% in het
verrichten van een echografie.
Er zijn verschillende testen beschikbaar om de D-dimeer concentratie te
meten. Waar oudere testen arbeidsintensief of te weinig sensitief waren,
zijn er nu nieuwe testen ontwikkeld die sneller en betrouwbaarder zouden
zijn. Nieuwe testen moeten echter klinisch gevalideerd worden. In hoofd-
stuk 6 onderzochten wij vier relatief nieuwe D-dimeer testen en vergeleken
deze met een klassieke D-dimeer test in opgeslagen bloed van 537 patiën-
ten bij wie een DVT vermoed werd. Deze patiënten maakten deel uit van
de studie die in hoofdstuk 5 beschreven is, en bij wie de D-dimeer concen-
tratie in eerste instantie gemeten werd met behulp van de Tina-quant® D-
dimeer test. Extra bloed werd verzameld om de D-dimeer concentraties op
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een later tijdstip te meten met behulp van de Asserachrom  ELISA®, VIDAS
New®, STA-LIA® en Miniquant® D-dimeer testen. Trombose werd ontdekt
bij 224 (42%) patiënten. ROC curves (sensitiviteit versus 1-specificiteit)
werden berekend voor elke test. De oppervlakte onder de curve is een maat
voor de bruikbaarheid van de test en was het hoogst voor de Tina-quant®.
Bij standaard (door de fabrikant aangegeven) grenswaarden waren sensi-
tiviteit, negatief voorspellende waarde en specificiteit van de Asserachrom®
respectievelijk 97, 94 en 33%. Deze waarden waren  res-pectievelijk 100,
96 en 8% voor de VIDAS New®; de Tina-quant® had waarden van respec-
tievelijk 99, 98 en 41%,  de STA-LIA® respectievelijk 98, 95 and 32% en
de Miniquant® respectievelijk 95, 94 en 52%. Aanpassing van de
grenswaarden waaronder de test normaal wordt geacht, resulteerde in een
verbetering van sensitiviteit en negatief voorspellende waarde, maar dat
ging (uiteraard) ten koste van de specificiteit. 
Deze studie toont aan dat de D-dimeer testen die hier gebruikt zijn allen
een hoge sensitiviteit en negatief voorspellende waarde hebben, maar geen
van allen bereikt een voorspellende waarde van > 98% bij standaard
grenswaarden. Voor het uitsluiten van trombose bevelen wij daarom aan de
D-dimeer test altijd te blijven gebruiken in combinatie met andere method-
en (zoals de klinische score) om het missen van de diagnose DVT te
beperken tot minder dan 1.0%. Het gebruik van een D-dimeer test met een
lage specificiteit is klinisch minder waardevol, omdat een positieve test altijd
gevolgd dient te worden door aanvullend onderzoek. 
Voor de behandeling van veneuze trombose is de effectiviteit van ongefrac-
tioneerde heparine (UFH) via een continu infuus bewezen. Het nadeel is
echter dat de patiënt hiervoor in een ziekenhuis dient te worden
opgenomen, en dat UFH een frequente meting van stollingparameters
vraagt voor een optimale dosisaanpassing. De behandeling met een één-
maal daagse, onderhuidse injectie van een laag-moleculair-gewicht
heparine (LMWH) heeft als voordeel dat dit thuis kan gebeuren en dat
monitoring van stollingsparameters niet noodzakelijk is. De behandeling
van longembolieën met LMWH is veilig gebleken, maar weinig is bekend
over verschillen tussen UFH en LMWH in veranderingen in de stolling
gedurende de eerste dagen na aanvang van de therapie. In hoofdstuk 7
vergelijken wij de effecten van UFH en LMWH op de stolling en de
afwijkingen op de longscan gedurende de eerste dagen van de behandeling
van longembolie. Zevenendertig patiënten met een acute longembolie wer-
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den behandeld met UFH (n=19) of met dalteparine, een LMWH (n=18).
Dagelijks werd op een vast tijdstip bloed afgenomen gedurende een peri-
ode van 5 dagen. De vorming van het stolsel (trombine productie) werd
gemeten door middel van fragmenten 1+2 (F1+2), trombine-antitrombine
(TAT)-complexen en fibrine monomeren. F1+2 en TAT-complexen nor-
maliseerden snel na start van de behandeling zonder verschil tussen de
twee groepen. De gemiddelde concentratie van fibrine monomeren daalde
in beide groepen niet, maar toonde zelfs een toename in de UFH groep
vanaf dag 3. De afbraak van het stolsel (fibrinolyse) werd gemeten door
bepaling van de D-dimeren concentratie en de clot-lysis tijd. De gemid-
delde D-dimeer concentratie daalde in de loop van de  tijd, zonder verschil
tussen de twee groepen. De clot lysis tijden waren korter in de UFH groep.
Na inactivatie van thrombin activatable fibrinolysis inhibitor (TAFI) door car-
boxypeptidase-inhibitor bleek heparine geen additioneel effect meer te
hebben op de clot lysis tijd. Dit bevestigt de gedachte dat het effect van
heparine op de clot lysis tijd voornamelijk door inactivatie van TAFI te verk-
laren is. Ventilatie-perfusie scans werden verricht waaruit de “percentage-
of-vascular-obstruction” scores (PVOs; een maat voor de grootte van de
longembolie) berekend werden op dag 0 (PVOsD0) en dag 5 (PVOsD5).
De daling van de PVOs op dag 5 ten opzichte van dag 0 was groter in de
LMWH groep.
Deze studie toont aan dat LMWH (dalteparine) minstens even effectief is
als UFH in het verminderen van de stollingsactivatie en de preventie van
toename van longafwijkingen. Dit ondersteunt het gebruik van LMWH in
de vroege behandeling van longembolie.
Veneuze trombose kan gepaard gaan met kanker, maar het routinematig
screenen op kanker bij iedere patiënt met een DVT is een punt van dis-
cussie. In hoofdstuk 8 onderzoeken wij of de initiële hoogte van de D-
dimeer concentratie of het beloop van de D-dimeer concentratie tijdens
behandeling van een DVT een voorspellende waarde heeft voor het
ontstaan of aanwezig zijn van kanker. Wij bestudeerden 218 patiënten met
een bewezen DVT, bij wie een D-dimeer test werd verricht. Patiënten wer-
den gevolgd gedurende gemiddeld 31 maanden en het ontstaan van
kanker werd gedocumenteerd. In totaal hadden of kregen 49 (22%)
patiënten kanker; 28 waren al bekend met kanker op het moment van de
DVT, bij 8 patiënten werd kanker ontdekt op het moment van de DVT en
13 patiënten ontwikkelden een kwaadaardige aandoening gedurende de
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follow-up periode. Bij een initiële D-dimeer concentratie kleiner dan 4000
µg/l kwam kanker bij 16% (20/128) van de patiënten voor, vergeleken met
32% (29/90) in patiënten met D-dimeer concentraties groter dan 4000
µg/l. Als de D-dimeer concentratie na 4 dagen behandeling kleiner dan
4000 µg/l was, kwam kanker voor bij 14% (6/44) van de patiënten,
vergeleken met 46% (6/13) van de patiënten met D-dimeer concentraties
groter dan 4000 µg/l. Een kwaadaardige aandoening werd vaker geconsta-
teerd bij patiënten ouder dan 60 jaar (37%) in vergelijking met jongere
patiënten (10%). Van alle patiënten met trombose en kanker bleek 78%
(38/49) ouder dan 60 jaar te zijn. Van de 13 patiënten die kanker kregen
gedurende de follow-up, was 85% (11/13) ouder dan 60 jaar. Bij patiënten
ouder dan 60 was er geen verschil in voorkomen van kanker tussen patiën-
ten met D-dimeer concentraties boven of onder 4000 µg/l. Bij jongere
patiënten daarentegen kwam kanker voor in 3% bij initiële D-dimeer con-
centraties kleiner dan 4000 µg/l en in 23% bij D-dimeer concentraties grot-
er dan 4000 µg/l. Indien de D-dimeer concentratie gemeten werd op dag 4
van de behandeling, bleek bij jongere patiënten met een waarde kleiner
dan 4000 µg/l een kwaadaardige aandoening in het geheel niet (0%) voor
te komen, terwijl alle (100%) jongere patiënten met D-dimeer waarden
groter dan 4000 µg/l kanker bleken te hebben. De onderzoeksgroep was
niet groot, maar indien onze bevindingen in een grotere studie bevestigd
kunnen worden dan zou screening op een kwaadaardige aandoening
vooral verricht moeten worden bij oudere patiënten en bij jongeren patiën-
ten bij wie in het begin of op dag 4 van de behandeling de D-dimeer con-
centratie hoger is dan 4000 µg/l.
Een overzicht en interpretatie van de recente literatuur betreffende de diag-
nostiek van DVT en met name de rol van de D-dimeertest en de klinische
score wordt gegeven in hoofdstuk 9.
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was je bereid om weer extra bepalingen uit te voeren. We hebben nog
genoeg in de vriezer, en ik hoop dat onze samenwerking nog lang zal
duren!
Barbara Kamp, Koos Dubbeldam, Paulien Oude Nijeweme en Carola van
der Hoek-Domburg, bedankt voor jullie toewijding in het verzamelen,
invriezen en registreren van de monsters van de AIDA studie en het uitvo-
eren van de semi-kwantitatieve Biopool test naast de Tina-quant.
Wim Gerritsen, als een stille (maar hard draaiende) motor ben jij bezig
geweest met de meeste analyses. De resultaten van dit boekje zijn in belan-
grijke mate van jou afhankelijk geweest. Duizendmaal dank voor je inzet. 
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Bep de Weerd, Jelle Adelmeijer, bedankt dat ik van jullie diensten in het
UMC gebruik mocht maken voor de bepalingen van de fibrine monomeren
en de clot lysis tijden.
Huub Haanen en Peter Slee (en de overige leden van de Maatschap Interne
in het St. Antonius ziekenhuis te Nieuwegein), bedankt voor het
vertrouwen dat jullie in mij hadden vanaf het begin dat ik de opleiding
interne bij jullie begon. Het voltooien van een proefschrift tijdens de opleid-
ing is geen makkelijke taak, en beiden waren onmogelijk geweest zonder
goede begeleiding.
Alle assistenten interne uit het St. Antonius ziekenhuis in Nieuwegein, het
Groene Hart ziekenhuis in Gouda, en het Diaconnessenhuis en het MESOS
ziekenhuis in Utrecht wil ik bedanken voor hun bijdrage in het aanmelden
van patiënten voor de AIDA studie. Zonder jullie was het belangrijkste deel
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Ik wil ook prof. dr. J.B. Hoekstra, dr. H.G. Peltenburg en dr. R. Oltmans
bedanken voor hun participatie in de AIDA studie. Multicenter studies zijn
de mooiste!
Mariëlle Beckers, dank je voor de verfijning van de follow up gegevens van
mijn laatste studie. We hebben veel lol gehad in het Antonius, in het UMC
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De longartsen, Hans-Jurgen Mager en Cees Westerman, wat een prachtig
idee was het toch om de D-dimeren te meten bij het emboliseren van
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De andere longartsen, Earl Esseboom en Repke Snijder, de opzet en
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De schrijver van dit proefschrift werd geboren op 15 augustus 1970 te
Leiden. In 1989 behaalde hij het Gymnasium B diploma aan het
Bernardinus college te Heerlen, waarna hij de studie geneeskunde startte
aan de Katholieke Universiteit Leuven te België. Het artsendiploma werd in
juni 1996 met onderscheiding behaald. Aansluitend volgde een arts-assis-
tentschap inwendige geneeskunde in het Groene Hart Ziekenhuis te
Gouda. De perifere opleiding tot internist ving aan op 1 januari 1998 in het
Sint Antonius Ziekenhuis te Nieuwegein (opleiders: dr. H.C.M. Haanen en
dr. P.Th.J. Slee). Tijdens deze perifere opleidingsperiode werden de ideeën
voor dit proefschrift verzameld en de daarbij behorende studies uitgevoerd.
In 2002 werd de opleiding voortgezet in het Universitair Medisch Centrum
Utrecht (opleider: prof. dr. D.W. Erkelens), alwaar de opleiding in april 2003
werd voltooid en hij thans werkzaam is als fellow haematologie (opleider:
prof.dr. A.H. Hagenbeek).
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ABBREVIATIONS
CUS = compression ultrasonography
DD = D-dimer
DVT = deep venous thrombosis
ELISA = enzyme linked immunosorbent assay
FEU = fibrinogen equivalent unit
FM = fibrin monomer
HHT = hereditary hemorrhagic teleangiectasia
LMWH = low molecular weight heparin
NPV = negative predictive value
PAVM = pulmonary arteriovenous malformations
PCP = pre-test clinical probability score
PE = pulmonary embolism
PPV = positive predictive value
PVOs = percentage of vascular obstruction score
Sens = sensitivity
Spec = specificity
TAFI = thrombin activated fibrinolysis inhibitor
TAT = thrombin-antithrombin
UFH= unfractionated heparin 
US = ultrasound
VTE = venous thromboembolism
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